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T-cell prolymphocytic leukemia (T-PLL) is a rare and poor-prognostic mature T-cell malignancy.
Here we integrated large-scale proﬁling data of alterations in gene expression, allelic copy
number (CN), and nucleotide sequences in 111 well-characterized patients. Besides prominent
signatures of T-cell activation and prevalent clonal variants, we also identify novel hot-spots for
CN variability, fusion molecules, alternative transcripts, and progression-associated dynamics.
The overall lesional spectrum of T-PLL is mainly annotated to axes of DNA damage responses,
T-cell receptor/cytokine signaling, and histone modulation. We formulate a multi-dimensional
model of T-PLL pathogenesis centered around a unique combination of TCL1 overexpression
with damaging ATM aberrations as initiating core lesions. The effects imposed by TCL1
cooperate with compromised ATM toward a leukemogenic phenotype of impaired DNA
damage processing. Dysfunctional ATM appears inefﬁcient in alleviating elevated redox bur-
dens and telomere attrition and in evoking a p53-dependent apoptotic response to genotoxic
insults. As non-genotoxic strategies, synergistic combinations of p53 reactivators and deace-
tylase inhibitors reinstate such cell death execution.
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T-cell prolymphocytic leukemia (T-PLL) is the most fre-quent mature T-cell leukemia1, yet with an incidence of≈0.6/million in Western countries, it is still an orphan
disease. It typically presents in the 6–7th decade of life at stages of
exponentially rising lymphocyte counts in peripheral blood (PB)
accompanied by hepato-splenomegaly, lymphadenopathy, and
bone marrow involvement1,2. Its chemotherapy-refractory beha-
vior adds to an inherent very poor prognosis (survival usually
<2–3 years)1,3,4. Even after common responses to the monoclonal
antibody alemtuzumab, eventually all patients relapse3. A major
reason for the limited therapeutic options to accomplish sus-
tained clonal eradication in T-PLL is our rudimentary under-
standing of its key disease mechanisms and molecular
vulnerabilities.
Karyotypes of T-PLL are often complex2,5–7 and include
recurrent rearrangements at chromosome (chr.)14, resulting in
juxtaposition of TCL1A (T-cell leukemia/lymphoma 1A) at
14q32.1 to T-cell receptor (TCR) gene enhancers8. This prevents
physiological post-thymic silencing of TCL1A. TCL1A is the
namesake of a 3-paralogue family9, further including TCL1B and
MTCP1. The X-chromosomal MTCP1 is involved in rare T-PLL
carrying the t(X;14) translocation. Transgenic (tg) mouse models
emulating human T-PLL illustrate the T-cell oncogenic potential
of TCL1A10 and MTCP111. Currently, the best established func-
tion of the 14 kDa TCL1A protein is an adapter-like engagement
in kinase complexes, formed upon antigen-receptor input,
resulting in enhanced pro-survival signaling5,12.
Deletions of chr.11q leading to losses of the tumor suppressor
ataxia telangiectasia mutated (ATM), as well as ampliﬁcations at
chr.8q represent additional highly prevalent abnormalities in T-
PLL2,5–7. While the sporadic form of T-PLL had been associated
with somatic ATM mutations13,14, it can also arise in cancer-
predisposed adolescents with ataxia telangiectasia (A-T) that
carry germline ATM inactivations15. ATM governs the main-
tenance of genomic integrity by orchestrating a proper DNA
damage response (DDR), including double-strand break (DSB)
repair, cell cycle control, and apoptosis regulation16,17. An ATM-
dependent response to DSBs activates p53 to enforce the G1
checkpoint for repair. Metabolic or redox-homeostatic roles (e.g.,
regulation of levels of reactive oxygen species (ROS)) are newly
recognized functions of ATM18. There are also non-canonical
DDRs in the absence of DNA damage, i.e., triggered by telomere,
mitotic, replicative, or oxidative stressors19.
Several series of genomic and transcriptomic proﬁling already
provided important insights into the genetic landscape of T-PLL
(data summarized in Supplementary Table 1). However, beyond
the implicated involvements of TCL1A, ATM, and JAK/STAT
genes20–24, there is still an incomplete understanding of their
phenotypic impacts and their molecular interplay towards T-PLL.
Here we report an integrated genetic and functional study on a
large T-PLL patient cohort to delineate the spectrum of altera-
tions and their mechanisms in T-cell transformation. For relevant
associations, we selected treatment-naive samples from patients
that were included in prospective trials or that were documented
in a nationwide registry, providing thorough clinical, immuno-
phenotypic, and cytogenetic data (in part provided in Supple-
mentary Data 1, Supplementary Fig. 1, Methods section).
As the dominant alterations of T-PLL’s molecular make-up, we
describe here a unique combination of TCL1-overexpression and
damaging ATM lesions. We characterize this functionally syner-
gistic interaction to signiﬁcantly contribute to T-PLL’s speciﬁc
phenotype of impaired proximal DNA damage processing and
abrogated p53-mediated cell death execution. We extract from
that targetable vulnerabilities and ﬁnally present a model of T-
PLL evolution resolved for pivotal genetic alterations integrated
with its landmarks of cellular dysfunctions.
Results
The hallmarks of dysregulated TCL1A and T-cell activation.
Array-based gene expression proﬁles (GEPs) of PB-isolated
tumor cells from 70 T-PLL exhibited a differential expression
(fold-change (fc)> 1.5, q< 0.05) of 2569 probes as compared to
CD3+ pan T-cells isolated from 10 healthy individuals. Of all
genes, TCL1A showed the highest dysregulation (fc = 33.9; q =
2.05 × 10−11, Student's t-tests; Fig. 1a). Importantly, as we pre-
viously implicated TCL1A as an ampliﬁer of T-cell signaling
input5, its upregulation was accompanied by deregulations of
TCR pathway modulators, suggesting a net enhancement of
antigen receptor and cytokine signaling in T-PLL. This included
reduced expressions of the negative-costimulatory CTLA4 (fc =
−6.92; q = 2.59 × 10−7), of the repressive T–T homotypic receptor
SLAMF6 (fc = −3.72; q = 2.06 × 10−9), or of the T-cell pro-apop-
totic GIMAPs (GIMAP5 fc = −3.34; q = 1.82 × 10−10), as well as
overexpression of TNF (fc = 9.98; q = 1.27 × 10−8), also known to
shape TCR signals (Fig. 1a, Supplementary Data 2). Upregulation
of immunosuppressive CD83 (fc = 5.69; q = 2.70 × 10−8) indicates
additional immune evasive properties.
Ingenuity pathway analysis (IPA) assigned the differentially
expressed genes to signiﬁcantly enriched clusters of proliferation,
cell cycle, survival, chemotaxis, immune responses, and inter-
mediates (i.e., ROS) of signal transduction (Supplementary
Fig. 2a, Supplementary Data 2). Gene set enrichment analysis
(GSEA)25 highlighted target genes of the transcription factor
MYC, signatures of γ-irradiation responses, or epigenetic
remodeling (Supplementary Fig. 2b). We conﬁrmed the deregu-
lated expression of genes associated with T-PLL in meta-
comparisons with small published cohorts at the global20 (GSEA;
Supplementary Fig. 2b) and gene-speciﬁc (e.g., CDKN1B26) level
(Supplementary Fig. 2c). qRT-PCRs validated the differential
expression for all of 21 selected transcripts (Supplementary
Fig. 2c).
The other TCL1 family members were consistently over-
expressed as well: TCL1B (fc = 4.53; q = 1.49 × 10−4) and
MTCP1p13 (fc = 2.65; q = 2.52 × 10−3; Supplementary Fig. 2c).
Overall, TCL1 family expression in 92.9% of T-PLL correlated
well with the cytogenetic detection of locus rearrangements in
94.6% of cases (Supplementary Fig. 2d). TCL1A levels correlated
inversely with patient survival (p = 0.7 × 10−3, log-rank test,
Fig. 1b). Further regression modeling provided a reﬁned score,
including RAB25 and KIAA1211L to predict less vs. more
aggressive clinical courses (Supplementary Fig. 2e, Methods
section).
Postulating an initiating role of dysregulated TCL1 genes, we
evaluated changes in GEPs in mice with early-onset T-lineage
speciﬁc overexpression of human (h) TCL1A (Fig. 1c). Already
sub-clinical ‘chronic’ phase expansions (Supplementary Fig. 2f, g)
from spleens of these Lckpr-hTCL1Atg mice revealed a differential
downregulation of CTLA4 and SLAMF6 (Fig. 1c) and many other
changes observed in human T-PLL (fc> |1.5|; p< 0.05; Supple-
mentary Data 3). This signature of T-cell activation in
conjunction with TCL1A-drive was preserved at the ‘exponential’
murine disease stage with additional deregulation of prominent
markers of transformation (Supplementary Fig. 2f, g, Supple-
mentary Data 3).
Whole-transcriptome sequencing (WTS) of 15 T-PLL vs. 4
normal T-cell isolates conﬁrmed the prominent TCL1A over-
expression and other top-scorers from the array-based GEP
analyses (Supplementary Figs. 3a, b, Supplementary Data 4).
Importantly, alternative TCL1A transcripts were detected (Sup-
plementary Fig. 3c). Tumor-associated alternative splicing was
indicated by 1927 segments in 1091 genes (|log2-fc| > 5, q< 0.01,
χ2-test) that showed differential exon usage in T-PLL over healthy
T cells (Supplementary Data 5). The most signiﬁcantly affected
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genes were involved in TCR/cytokine signaling and p53
associated apoptosis regulation (Supplementary Fig. 3d, Supple-
mentary Data 5).
Copy number losses of ATM and novel gains at chromosome
8q. Based on the detected average abundance of large-fragment
genomic lesions in our set (n = 83), T-PLL is positioned near the
‘complex’ end of the spectrum of somatic copy-number altera-
tions (sCNAs) of hematopoietic and solid cancers (Fig. 2a). The
most frequent sCNAs (compared to pooled germlines from 13
cases / HapMap controls) were found at chr.11 (37%/52%), chr.8
(29%/42%), chr.22 (24%/24%), and chr.13 (14%/14%) (Fig. 2b).
GISTIC2.0 analyses underlined the signiﬁcance of those promi-
nent lesions (Supplementary Data 6, Supplementary Fig. 4a). The
inv(14) and t(14;14), detected in 93% of this set by FISH/kar-
yotyping, were predominantly copy-neutral. We identiﬁed
recurrent (affected in >20% of cases) gains (CN> 2.5) in 637
genes and losses (CN< 1.5) in 1685 genes (Supplementary
Fig. 4b, Supplementary Data 7). The presence of complex kar-
yotypes (>3 large-scale aberrations), a determinant of poor-
outcome subsets in a recent series of T-PLL6 and in other leu-
kemias, was a rather uniform feature here (89.5%).
Aberrations on chr.11 and chr.8 are described for T-PLL and
have been intuitively linked to alterations of ATM and MYC. We
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Fig. 2 Large-scale genomic aberrations dominantly involve losses of ATM on chr.11q and gains of AGO2 andMYC on chr.8q. a Number of differentially sized
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HapMap controlled, meta-analysis procedure in Methods section). b Ideograms with average abundance of large-scale genomic lesions (Supplementary
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test)
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deﬁned here the minimally deleted and ampliﬁed regions (MDR/
MAR) of these most prominent hot-spots compared to patient-
derived germlines (Fig. 2c, Supplementary Fig. 4c). The chr.11
MDR was represented by strictly monoallelic losses of ATM
found in all MDR-affected cases (31/83, 37.4%, average CN =
1.79; HapMap controlled). Often co-deleted adjacent to this MDR
were the P53-suppressor network micro-RNAs miR34b/c (Sup-
plementary Fig. 4b). Genes encoding for downstream effectors of
ATM were disrupted in a minority of T-PLL (e.g., CHEK2 13.3%;
TP53 4.8%).
In contrast to the assumption of MYC being the primary target
of the chr.8 associated gains, we identiﬁed AGO2 (argonaute RISC
catalytic component 2) to deﬁne this MAR, that was present in
28.9% of cases (51.2% when HapMap controlled; average CN =
2.22; Fig. 2c). MYC gains were involved in only 70.8% of T-PLL
harboring a MAR on chr.8 (average CN = 2.17; Supplementary
Fig. 4b, Supplementary Data 7). The AGO2 gains were validated
using a FISH probe and were associated with AGO2 over-
expression (Fig. 2d, Supplementary Fig. 4d, e). AGO2 is
frequently overexpressed in cancer27 and has been increasingly
considered a pivotal mediator of oncogenic miR/siRNA biogen-
esis28 with emerging functions in chromatin remodeling and
alternative splicing29. In agreement with current paradigms of
cancer gene activity30 and further implicating a relevance of
altered miR/siRNA processing factors in T-PLL, we identiﬁed
uniparental disomies (UPDs) of AGO1/-3/-4 (all on chr.1) in
68.7% of cases (n = 57/83; against HapMap; Supplementary
Data 7).
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Fig. 3 Novel structural variations and fusion transcripts. a Whole-genome sequencing (WGS) of 3 T-PLL t/g-pairs to map intra- and inter-chromosomal
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In accordance with their molecular functions31,32, ATM losses
and AGO2 over-representations were each associated with a
higher degree of CN-lesional genomic complexity outside their
own affected regions (Fig. 2e) and with speciﬁc GEPs, e.g., chr.11
MDR with dysregulated SLAMF6 or chr.8 MAR with reduced
CTLA4 (Supplementary Fig. 5a–c, Supplementary Data 8,9).
Among the prominent CN lesions, ATM sCNAs were of negative
prognostic impact (p = 0.02, log-rank test, Fig. 2f; similar to lower
ATM transcript levels Supplementary Fig. 5d).
Generally, CN losses/gains were not strictly linked to altered
expressions of the affected genes (Supplementary Figs. 4e, 6a–c,
7), likely because of not depicted regulatory aspects (e.g., allele-
dominances or LOH scenarios). Conversely, the reductions in
ATM transcript levels were also found in chr.11 MDR-negative
cases and the uniformly increased MYC expression was
independent of the presence of a chr.8 gain (Supplementary Figs.
4e, 6a–c, Supplementary Data 2). Both suggest additional modes
of dysregulation beyond sCNAs. This was recapitulated in
TCL1A-initiated murine T-PLL: although the proliferations of
Lckpr-hTCL1Atg mice lacked ATM and MYC sCNAs, they
harbored reduced and increased expression of these genes,
respectively (Supplementary Fig. 6d, e).
New gene fusions in high-resolution DNA and transcript
assessments. Somatic intra- and inter-chromosomal structural
variations (SVs) detected by whole-genome sequencing (WGS, n
= 3) revealed a high heterogeneity among cases. COSMIC listed
SVs recurrently affected chr.8, 11, 14, 16, and 21 (Fig. 3a, Sup-
plementary Data 10). Fusion transcripts identiﬁed in WTS (15/15
cases; Supplementary Data 11; by TopHat-Fusion) with corre-
sponding SVs in whole-exome sequencing (WES) data (n = 17)
included the hybrids: JAK2 (chr.9) - TCF3 (chr.19), TRIM22
(chr.11) - JAK2, and KANSL1 - ARL17A (both chr.17), each in 1
case. Three chr.8-intrinsic fusions involving PLEC with varying
partners (GRINA, CYHR1, and SHARPIN) (Fig. 3b) were likely
the result of the complex rearrangements at chr.8. A SEPT-ABL1
hybrid reported in an anecdotal T-PLL33 or fusions found in
nodal mature T-cell lymphomas34 were not identiﬁed.
Overall, the inv(14) or t(14;14) were the most common
structural aberrations (3/3 by WGS, 14/17 by WES; Fig. 3c,
Supplementary Fig. 8a, Supplementary Data 10). In TP003 the inv
(14) links TCL1A to TRAJ49. This fusion transcript was validated
with multiple callers (Methods section) and by RT-PCR
combined with Sanger sequencing. It is the ﬁrst report of a
TCL1A fusion instead of the usual in-trans positioning, with
validated mRNA and protein expression (Fig. 3b, d, Supplemen-
tary Fig. 8b). In conjunction with the data on sCNAs, there were
no indications for chromothriptic events35,36.
Prominent patterns and pathways of the mutational landscape.
Having identiﬁed alterations in TCL1A, ATM, AGO2, or MYC as
highly prevalent lesions, we next assessed the contribution of
mutations (single-nucleotide variants (SNVs) and small indels
(insertions and deletions)). Samples from 72 patients were sub-
jected to WGS (three tumor/germline (t/g)-pairs, 1 tumor ‘sin-
gle’), WES (17 t/g-pairs; 37 singles), targeted-amplicon
sequencing (TAS; n = 18), and Sanger resequencing (platform
overlap in Supplementary Fig. 1a). Puriﬁcation and separation of
t/g-paired material in a 2-step cell-sorting procedure ensured
average tumor purities >98% and contamination rates <2% in
germline isolates (Supplementary Fig. 1b). This high purity,
together with the generally diploid karyotype of T-PLL cells
(overall CN 1.97 based on TitanCNA and the 17 t/g WES pairs)
facilitated speciﬁc somatic calls and reliable calculations of variant
allele fractions (VAFs) and cellular prevalences (formerly ‘cancer
cell fractions’ (CCFs)) for estimations of (sub)clonal sizes (Sup-
plementary Data 12). To identify mutations likely to be biologi-
cally relevant, we applied various stringent thresholds, e.g., 8-
oxoguanine (8-Oxo-G) allelic imbalance ﬁlter37,38, false-discovery-
rate (FDR) based MuSiC39 analysis, required COSMIC data base
hit, minimum population frequency (PopFreq) <0.01, and pre-
diction to be damaging (SIFT, PolyPhen2,PROVEAN).
Characteristic global patterns of mutations: The median rate of
exonic somatic mutations in T-PLL of ~1.1 Mut/Mb was similar
to other hematologic and solid neoplasms (Fig. 4a; Supplemen-
tary Data 12). Regional annotations, e.g., exonic or splice-site, are
summarized in Fig. 4b. When compared to other catalogued
cancer genomes40, the mutational proﬁle of T-PLL revealed
striking similarities to the signatures of ‘aging’ (ρ = 0.65; p = 8.9 ×
10−13) and ‘smoking’ (ρ = 0.62; p = 2.1 × 10−11, Spearman correla-
tions, Supplementary Fig. 9a). This points at a prominent role of
non-predispositional cumulative insults in T-PLL. In fact, we
noticed enrichments of C:G>A:T transversions implicating the
presence of high-level genotoxic, i.e., oxidative, stress41 (Fig. 4c,
Supplementary Fig. 9b). Fittingly, immunoﬂuorescence stains for
8-Oxo-G marks of oxidative DNA damage, a major source of
deleterious G> T exchanges, indicated higher loads in T-PLL
cells over normal T cells (Fig. 4c, Supplementary Fig. 9d; p =
0.005, Student’s t-test). In further support, levels of ROS induced
upon TCR stimulation were higher in primary T-PLL cells than in
healthy-donor T cells (Supplementary Fig. 9c; p = 0.042, Student’s
t-test). Since T-PLL cells resemble memory T-cells5, a long-lived
subset predestined to accumulate high amounts of DNA damage,
we also compared the WES-derived mutational proﬁles of T-PLL
to those of memory T-cells isolated from 3 age-matched healthy
donors (ages 61, 63, and 65 years), with memory T cells from 3
young donors (22, 28, and 31 years) as controls. It revealed
signiﬁcant differences in the relative distribution of base
alterations in speciﬁc trinucleotide contexts (p = 0.2 × 10−3,
Wilcoxon test), particularly a higher prevalence of C:G >A:T in
T-PLL (Fig. 4c, Supplementary Fig. 9b). Together, these data
suggest that oxidative damage in T-PLL is enriched by inefﬁcient
repair mechanisms that fail to counteract these speciﬁc genotoxic
hazards of ‘T-cell aging’.
Pathways recurrently affected: A ranking of the genes affected
by SNVs and indels identiﬁed in WES t/g-pairs and WES t-singles
(Fig. 4d, e, Supplementary Fig. 10a) highlighted ATM (64.8%, 35/
54 cases) and STAT5B (27.8%; 15/54) by highest frequencies.
Potential biological signiﬁcance could also be ascribed to less-
often mutated genes based on their clustering in pathways like the
DDR, i.e., its branch of mismatch repair (MSH3, MSH6).
Epigenetic modulation was another prominent cluster, e.g.,
represented by a high incidence of the mutated histone methyl
transferases KMT2C, KMT2D, and KMT5A cumulatively in 61%
(33/54) of cases. Other recurrently affected pathways were
apoptosis/survival signaling and cell cycle regulation (Supple-
mentary Data 12 and GSOA in Supplementary Fig. 10b).
Potential driver mutations: In the 17 WES data sets of paired t/
g-samples allowing stringent background estimation, 26 genes
were identiﬁed as signiﬁcantly mutated (MuSiC39 with FDR<
0.1; Supplementary Data 13), including ATM, JAK3, STAT5B,
ILK, CDC27, and CXCR4 (Fig. 4d, red asterisks). When pooled
with the 37 pseudosomatic singleton WES data sets, genes
identiﬁed as signiﬁcantly mutated (n = 668 total, Supplementary
Data 13) further included IL7R, EZH2, MLH1, HIST1H1A,
KDM1B, FAT2, SAMHD1, and FASTKD1. This conﬁrms the
relevance of disturbed DNA repair, cytokine or apoptotic
signaling, and epigenetic regulations. Importantly, only a small
number of SNVs and indels showed high VAFs / cellular
prevalences of 80–100%. This total of 16 genes (1.4%) in 11/17
cases included SAMHD1, USP9X, or FASTK. However, ATM was
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the only gene harboring highly recurrent mutations with a
cellular prevalence >80%, thus most likely represents a common
driver in T-PLL (Supplementary Data 14, Fig. 4e, Supplementary
Fig. 10c for all mutations).
Co-occurrence of mutations and copy-number events: Integra-
tion of sCNA and WES data to speculate on selection for
dysfunctional targets revealed that 192 of the 6970 mutated genes
(including read-throughs) were affected by gain-of-function
(GOF, CNV> 2.2, VAF> 0.5) or loss-of-function (LOF, CNV
< 1.7, VAF> 0.5) aberrations. Somatic mutations combined with
focal gains/losses were found in 72% (n = 39/54) of cases. They
dominantly included the DDR master regulator ATM (19/54
WES cases) and the histone-Lysine N-methyltransferase EZH2 (3
cases; Fig. 4f, Supplementary Data 15). This emphasizes the
particular relevance of genes associated with DNA repair and
epigenetic regulation. Further genes simultaneously affected by
sCNAs and SNVs/indels, included POT1, JAK1, and PCM1,
which are all linked to hematologic malignancies. Associations of
SNVs/indels with UPDs were found in 81.5% of cases, affecting
321 genes including STAT5B (3 cases) and ATM (3 cases). We
observed a signiﬁcant co-occurrence of mutations affecting
STAT5B and ATM (p = 0.045, Fisher’s exact test), suggesting an
accessory role of STAT5B in T-PLL tumorigenesis. Only 9.7% of
T-PLL were neither ATM nor JAK/STAT mutated. Further
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associations are depicted in the multivariate q-value matrix of
Supplementary Fig. 10d.
Subclonal JAK/STAT variants: The observed high frequencies
of mutations in JAK/STAT signaling components, shown
previously also in smaller series21–23,42, underline their somatic
character. However, their low and generally CN-neutral VAFs
implicate these lesions rather as subclonal events (Fig. 4e).
Combining all sequencing approaches employed here, IL2RG
(3.7%), JAK1 (5.6%), STAT5B (23.6%), or JAK3 (33.3%) were
mutated in a total of 61.6% of the 72 analyzed T-PLL. These were
predominantly mismatch mutations in the SH2 (STAT5B) and
pseudo-kinase (JAK1/JAK3) domains (Fig. 4g). Basal phosphor-
ylation states of activating JAK/STAT motifs were elevated in T-
PLL over normal T-cells (Supplementary Fig. 11a, b; pSTAT5B-
Tyr694; human: p = 0.017; murine hTCL1A-tg leukemia: p = 0.054,
Student’s t-test). This was not restricted to JAK1/JAK3/STAT5B
mutated T-PLL. In fact, genomic losses of negative JAK/STAT
regulators like the phosphatases DUSP4 or SOCS3, found in 33
and 8% of our cases, respectively, implicate alternative activating
mechanisms. JAK/STAT mutated and -unmutated T-PLL showed
similar extents of STAT5B phospho-activation in response to
interleukins (Supplementary Fig. 11c). To interrogate for a
differential activating potential of the STAT5B mutations, we
overexpressed N642H (most frequent), T628S, D634V, and
V712E (outside SH2 domain, not reported for T-PLL) in model
cell lines (Supplementary Fig. 11d, e). Particularly N642H
conferred elevated basal levels of phospho-STAT5BTyr694.
N642H and V712E conveyed a signiﬁcant pro-survival effect in
IL-3 dependent 32D cells (p< 0.0001 and p = 0.0002, Student's t-
tests; Supplementary Fig. 11e).
Mutations in ATM reveal clustering in functional domains.
Variants of ATM were detected in 48/72 (67%) of cases (WES and
TAS; Fig. 5a). They were mostly missense SNVs (n = 42/49 dis-
tinct mutations), less frequently nonsense SNVs (n = 4/49), or
frameshift indels (n = 3/49), unlike the predominantly truncating
lesions found in A-T individuals43 (Fig. 5a, Supplementary Fig.
12a). We cataloged lesions at 36 unreported localizations. Pre-
vious studies of low sample numbers each individually suggested
an unbiased distribution of ATM mutations in T-PLL across the
molecule. However, our data, enriched for somatic calls, revealed
for the ﬁrst time a clustering of mutations in the FAT (31%) and
PI3K (16%) domains. A meta-analysis of our and published data
on ATM mutations in T-PLL further emphasized this (Supple-
mentary Fig. 12b).
Integrating the data on GE, sCNA, and mutation proﬁling
showed that the vast majority of T-PLL was affected by
monoallelic deletions or/and mutations of ATM (44/54, 81%;
Fig. 5b). These cases generally showed a reduced ATM transcript
abundance (global fc = −2.32, q = 2.2 × 10−11 vs. normal T-cells,
Student's t-test). Generally, downregulated ATM expression was
associated with signiﬁcant reductions of 5 of 7 protein encoding
transcript variants (WTS analysis of 15 T-PLL vs. 4 healthy T-cell
controls; fc > |1.5|; p-values from p = 3.4 × 10−5 to p = 0.04,
Student's t-tests; Supplementary Fig. 12c).
Most frequently, ATM was subject to an LOH event (CN< 1.5;
ATM mutated, VAF> 20%) (n = 24/54, 44%), also reﬂected by
signiﬁcant co-occurrence of ATM mutations with ATM sCNAs
(p = 0.0046; odds ratio 4.33, Fisher’s exact test; Supplementary
Fig. 10d). ATM expression in the 17 T-PLL with an unmutated
ATM sequence was unchanged in the CN-biallelic subset (n = 10,
fc = 1.13), but highly deregulated in the CN-monoallelic cases (n
= 7, fc = −3.26).
The 10 ATM CN-biallelic/unmutated T-PLL included one case
with a TP53 mutation (TP032; p.X215Q; VAF = 0.23; CN = 2),
one case with a BRCA1 mutation (TP093), 3 SAMHD1 mutated
cases (TP026, TP027, and TP031), and 3 cases (TP033, TP047,
and TP081) with multiple damaging mutations in pro-apoptotic
and epigenetic regulators, e.g., FASTKD1, CASP10, KMT2C, and
DNMT3A. The remainder of 2 cases (TP051, TP052) was only
subjected to the selected TAS panel.
Longitudinal changes in clonal compositions. To reconstruct
hierarchies of chronological alterations, we analyzed serial sam-
ples from diagnosis / before therapy vs. progression / post-ther-
apy relapse of 5 patients (constant sample purities;
Supplementary Fig. 13a). Such progression-associated changes or
those selected by therapy were most prominent at the global
mRNA level (Supplementary Fig. 13b, Supplementary Data 16).
Gene CNAs suggested sequential increases in global complexity
(1.4-fold, p = 0.06, Wilcoxon test, Supplementary Fig. 13c, Sup-
plementary Data 17). As expected, for the majority of gene
mutations cellular prevalences remained unchanged, but speciﬁc
time-point restricted calls (clusters) existed (Supplementary Fig.
13d, Supplementary Data 18). Differential calls at progression or
relapse were markedly enriched for genes associated with ‘inter-
leukin-‘ and ‘STAT3 signaling’ (p = 0.27 × 10−4, hypergeometric
tests via ConsensusPathDB, Supplementary Data 19), dictated by
dynamics of subclone sizes of mutated JAK1, JAK3, or STAT5B
(Fig. 5c). Variants with exclusively increasing cellular prevalences
were annotated to ‘ATM-/TP53-regulated transcription of DNA
repair genes’ (p = 0.00049) and ‘Notch signaling’ (p = 0.00065;
Supplementary Data 19).
Fig. 4 The mutational landscape of T-PLL - recurrent patterns and pathways. a WES of 17 T-PLL t/g-pairs: meta-analysis (details in Methods section)
comparing the mutation frequency in T-PLL to other malignancies (* 2 cases with T-LGL were sequenced as part of this study). b Number of somatic SNVs
and small indels per t/g-pair resolved for locations and characteristics (also Supplementary Data 12); overall 1141 distinct SNVs and indels: 9 frameshift
insertions, 22 frameshift deletions, 17 non-frameshift deletions, 10 non-frameshift insertions, 745 non-synonymous, 20 splice sites, 79 ncRNA CDS,
38 stop-gains, 1 stop-loss, 178 within UTRs, and 22 alterations of unknown function. c Bars: median numbers of base exchanges calculated in the 17 t/g-pair
WES data sets revealed a relative enrichment of C:G>A:T transversions (Odds ratios (ORs) 1.3 for G> T and 1.6 for C>A) compared to age-matched
normal memory T-cell samples, while C:G> T:A are underrepresented in T-PLL (p= 0.008, Fisher’s count test). The ranks of substitutions were
signiﬁcantly different, with C:G>A:T at 4/12 and 3/12 in T-PLL and at 6/12 and 8/12 in donors age-matched memory T-cells (p= 0.0002; Wilcoxon test;
Supplementary Fig. 9b). Panels: Immunoﬂuorescence microscopy using an 8-OxoG speciﬁc antibody in T-PLL cells (right) vs. healthy-donor derived pan T-
cells (left) (scale bar= 5 µm). See Supplementary Fig. 9d for quantiﬁcation and technical controls. d Mutated genes (including SNVs and indels;
frequencies are font-size coded) identiﬁed in n= 17 t/g-pairs and n= 37 t-singles by WES. e Left: frequencies of T-PLL cases affected by mutations in a
selection of genes based on frequencies in the cohorts of 17 t/g-pairs (red) and 37 t-singles (rose). Right: mean VAFs of the selected genes over all
mutated cases in the 17 t/g-pairs (interquartile range (IQR); mean with upper and lower limits). f Integrated WES and sCNA-proﬁling data to identify genes
with gain-of function (GOF, CN> 2.2, VAF> 0.5) and loss-of-function (LOF, CN< 1.7, VAF> 0.5) aberrations. gMissense mutations in JAK3, STAT5B, and
JAK1 genes identiﬁed by WES and targeted-amplicon sequencing (TAS). Conﬁrmed somatic: t/g-pairs (WES: n= 17); potentially somatic: tumor singles
(WES: n= 37; TAS: n= 18)
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TCL1A and ATM as the most recurrently affected genes in T-
PLL. We summarize in Fig. 6a, b the lesional landscape of T-PLL
in a global gene-centric integration across all analyzed cases.
Dysregulated TCL1A mRNA or protein expression and structural
variations involving the TCL1A or MTCP1 locus were detected in
94% of samples. Somatic losses and mutations affecting ATM,
associated with signiﬁcant mRNA downregulation, were identi-
ﬁed as highly prevalent as well (86%). Beyond that, 69% of cases
were affected by at least one of the other key aberrancies, i.e.,
sCNAs of chr.8 or mutations in JAK/STAT genes. Finally, aber-
rant expression of genes associated with the canonical DDR or
with epigenetic regulation was inherent to 93% of T-PLL. To
further substantiate a disease model, functional studies, i.e.,
centering on phenotypic outcomes of ATM and TCL1A dereg-
ulation, were undertaken.
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Impaired damage responses implicate a functionally hypo-
morphic ATM. The complex karyotypes of T-PLL suggest a
high genome instability. Given the recurrent ATM lesions, we
implicated abrogation of central functions of this apical master
regulator of the canonical DDR as the foremost cause. In agree-
ment with ATM’s other recognized roles in regulating ROS levels
and telomere lengths, we described the elevated redox burden
(Fig. 4c, Supplementary Fig. 9d; p = 0.005, Student's t-test) and
demonstrated markedly shortened telomeres (p< 0.0001, paired
Student’s t-test; Fig. 7a, Supplementary Fig. 14a–c); the latter
corroborating a previous observation by others44.
We next examined the capacity of the leukemic cells to mount
an adequate response to DSBs. T-PLL cells showed aberrant
cytosolic retention of ATM protein upon damage induction via
Etoposide (median nuclear fraction 78.6% in normal PBMCs vs.
42.5% in 11 T-PLL, p< 0.0001, Student’s t-test; Fig. 7b,
Supplementary Fig. 14d). Furthermore, the kinetics of induction
and resolution of induced DSB platforms marked by ATM’s
target γH2AX were aberrant (different from normal T-cells) in 19
of 23 T-PLL as analyzed in time-lines of western blots and
microscopic focus counts (Fig. 7c, Supplementary Fig. 15). This
mainly included cases with elevated marks at baseline and a
protracted resolution, but also comprised a subset (5/19) with
hardly any noticeable basal and stimulated γH2AX. These data
implicate impaired proximal damage sensing and processing.
Besides dysfunctional ATM, this could also be due to primary
defects of γH2AX, as these are also T-cell lymphomagenic45 and
given the monoallelic losses of the H2FAX locus in 22.9% (19/83)
of our T-PLL. Therefore, we further recorded activation of the
ATM-speciﬁc substrate and heterochromatin builder KAP146
(Supplementary Fig. 16a, b). KAP1 phosphorylation in response
to γ-irradiation was noted in 16/23 cases, as deﬁned by >20% of
the level of immortalized control lymphocytes from a healthy
ATM-wt member of an A-T pedigree. However, 30% (7/23) of
cases displayed a diminished or absent response. Lower pKAP1
responses were predominantly seen in cases with aberrant
γH2AX induction (p = 0.0065, Mann–Whitney U-test; Supple-
mentary Fig. 16c). Complete abrogation of pKAP1 induction was
found in the rare T-PLL with truncating ATM mutations (e.g.,
TP053) in analogy to ATMmut/mut lymphoid A-T cells, while most
ATM-biallelic/wt cases were more pKAP1 responsive (Supple-
mentary Fig. 16a–c).
Overall, we conclude that despite genomic ATM defects, there
is preserved γH2AX / pKAP1 induction in most T-PLL, but often
at sub-maximal levels or with altered kinetics of proximal
platform recruitment and resolution.
TCL1A contributes to the aberrant telomere, ROS, and DDR
phenotype. In contrast to ATMnull A-T cells, the ATM lesions in
T-PLL are obviously not associated with elevated chemo-/
radiosensitivity. This might be linked to the residual functions of
the mutated ATM (above, Fig. 7c, Supplementary Figs. 15b,16)
and could also involve a rescue relationship with anti-apoptotic
TCL1A. Consequently, we modeled the speciﬁc impact of TCL1A
after introduction into the ATM-biallelic mature T-cell leukemia
lines HH (inducible; Supplementary Fig. 17a) and Hut78 (stable).
In resemblance of the phenotype of T-PLL cells, TCL1A propa-
gated telomere shortening (p = 0.039 at 8 weeks, Student’s t-test;
Fig. 8a, Supplementary Fig. 17b–d) and higher γ-irradiation-
induced ROS levels (p = 0.017, Student’s t-test, Fig. 8b). This was
likely not attributed to replicative stress, as there was no pro-
proliferative effect by TCL1A (Supplementary Fig. 17e). Fur-
thermore, in the presence of TCL1A, the extent of induced DSBs
was increased and their processing was markedly protracted, as
per kinetics of γH2AX, RAD51, and TP53BP1 foci and γH2AX
expression levels (Fig. 8c, Supplementary Fig. 17f–h).
We next interrogated scenarios of deﬁcient ATM. For that, we
introduced TCL1A into immortalized murine embryonic ﬁbro-
blasts (MEFs) carrying transgenes for the conditional expression
of the ATM variants ATMﬂ/wt (monoallelic loss) or ATMﬂ/KD
(PI3-kinase dead (KD) mutation)43, mimicking the lesions
identiﬁed in T-PLL. We observed protective effects of TCL1A
expression in response to γ-irradiation in both lines of ATM
disruption (p = 0.031 (ATMﬂ/wt), p = 0.045 (ATMﬂ/KD), Student's
t-tests; Fig. 8d, Supplementary Fig. 18a). Similarly, TCL1A
mitigated the irradiation-induced reductions in Hut78 T-cell
viability (p = 0.034), particularly in the context of inhibition of
ATM activity by KU-55933 (p = 0.026, paired Student's t-tests;
Supplementary Fig. 18b).
A pro-leukemogenic cooperation of TCL1 with ATM deﬁ-
ciency. We asked whether there are pro-tumorigenic synergisms
between TCL1A overexpression and genomic ATM loss in mice.
A design of TCL1A overexpression initiated in hematopoetic
precursors followed by induced ATM depletion after engraftment
in syngeneic hosts allowed assessments for lineage biases and
error-prone DSBs during physiological V(D)J gene rearrange-
ments to take place. Induction of thymic T-cell lymphomas/leu-
kemias, which were more aggressive in ATM−l−/hTCL1Atg
animals (median survival 221 days) than those induced by the
single-hit genotypes (ATM−/−/GFP+, 500 days, p = 0.028; ATMﬂ/
ﬂ/hTCL1Atg, 416 days, p = 0.042, log-rank tests; Fig. 8e, Supple-
mentary Figs. 18c,d), provided afﬁrmation of a TCL1/ATM
cooperation.
Pharmacologic targeting of the dysfunctional ATM/p53 axis.
Pro-apoptotic signaling in response to most kinds of DNA
damage is centrally relayed through activation of p53. In our
cohort of T-PLL, sCNAs (4.8%, 4/83 cases) and mutations (3.7%,
2/54 cases) that disrupt TP53 were rare. P53 regulators were also
Fig. 5 ATM sequence variants and dynamics of clonal compositions. a ATM mutations identiﬁed in WES (54 cases) and TAS (18 cases) mapped on the
schematic polypeptide strand show clustering in the FAT (21/67 (31%) total mutations) and PI3K (11/67 (16%)) domains (* denotes nonsense mutation).
See Supplementary Fig. 12a,b for validations and meta-analysis with published ATMmutations in T-PLL. b Integration of ATM CNs, VAFs, and mRNA levels
in 54 T-PLL with complete platform overlap (3 sequential samples: TP092, TP093, TP094). Largest subsets among the 44 CNA/mutation affected cases:
LOH genotype (enriched FAT domain mutations; p= 0.0079, Fisher’s count test) followed by ATM-mutated/CN-biallelic cases (enriched frameshift or
nonsense mutations; p= 0.021, Fisher’s count test). UPDs in 3 cases: TP010, TP023, and TP054. c Five sequential samples analyzed by WES. Top: VAFs
for single mutations are copy-number- and contamination-corrected to obtain cellular prevalences based on Bayesian models (PyClone; Supplementary
Data 18 for all genes). For illustrative purposes the prevalences of mutations between time points carry dashed connectors for better visual guidance,
although such clonal dynamics likely do not follow a strict linear function. There were redundant and prominent changes in relative subclonal ‘sizes’ of
JAK1/JAK3/STAT5B variants. The increase in cellular prevalence of ATML1238* in treatment-naive TP094 at t2 was attributable to a loss of the remaining wt-
allele (CN< 1.5, Fig. 5b). This was accompanied by a further downregulation of ATM mRNA (fc= −1.63 vs. fc= −2.35). Bottom: Clone sizes of clusters (‡)
containing mutations shown in the top panels (identiﬁed via PyClone). The JAK3 changes in cases F/U4 and F/U5 corroborate the inverse relationship of
JAK3 and ATM variants (Supplementary Fig. 10d). For longitudinal changes in GEP and sCNAs see Supplementary Data 16, 17
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very infrequently affected (Fig. 9a). Given the preference for ATM
lesions and the outlined phenotype of partial loss of ATM
function (above), we tested whether p53 could still be activated
via the ATM/CHEK2 route. Upon γ-irradiation, irrespective of
any pATMS1981 induction (retained in 8 of 9 cases), T-PLL cells
failed to generate a pP53 response in all 9 analyzed samples
(Fig. 9b; accompanied by lack of pCHEK2 induction in 4/6 cases,
Supplementary Fig. 19a). This deﬁcient upstream activation
would implicate that the apparently genetically intact, hence
functional, p53 is retained in its inactive state.
Such a tonus of p53 inactivity is usually mediated by higher net
binding to its repressor MDM2 and deacetylation of its functional
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differentially expressed genes associated with epigenetic regulators (7; Supplementary Data 20) or DDR (8; Supplementary Data 21). Each case was
affected by at least one of these core lesions
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domains. Consequently, in a proof-of-principle approach we
interrogated T-PLL cells for vulnerabilities around their ATM/
p53 incompetence. We applied the MDM2-inhibitor Idasanutlin
as a pharmacologic backbone of p53 de-repression and
investigated co-operations with selected other classes of com-
pounds. Several notions prompted us to additionally target
chromatin remodeling and protein deacetylation by a histone
deacetylase inhibitor (HDACi; Panobinostat): (1) our proﬁling
data identify various recurrent lesions in DNA repair molecules
and histone modiﬁers (Figs. 4, 6, Supplementary Data 12; 91.7%),
(2) DNA-repair viably depends on histone modiﬁcations46, (3)
sufﬁcient activation of p53 and ATM involves their direct HAT
mediated acetylation47,48, (4) HDACi’s show a particularly high
activity in T-cell tumors and can revert resistance in T-PLL49. For
additional DSB induction we opted for the nucleoside-like
alkylator Bendamustine, because of its clinical activity in T-
PLL50. A fourth class of substances, PARP-inhibitors (here
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Olaparib), was chosen based on the well-established synthetic
lethal relationship with defective ATM51.
Idasanutlin at sub-LD50 concentrations reinstated repressed
phospho- and acetyl-marks of p53 activity in T-PLL cells (Fig. 9c,
Supplementary Fig. 19b). This was enhanced by co-treatment
with sub-LD50 dosages of Panobinostat or Bendamustine. As
single agents, Idasanutlin and Panobinostat profoundly and
selectively induced apoptosis in T-PLL cells with LD50s in the
nM range (Supplementary Fig. 19c). In a combinatorial matrix of
the 4 substances (each at 7 concentrations over a 103-fold range)
we then interrogated for over-additive interactions affecting cell
viability in 13 T-PLL (Fig. 9d). Synergisms in low-mid nM-ranges
were identiﬁed for all Idasanutlin combinations, which were
particularly active when involving the HDACi Panobinostat.
Finally, in a pilot experiment of mice transplanted with leukemic
CD2-MTCP1p13 cells, Idasanutlin reduced T-PLL burden in blood
(p = 0.048) and spleens (p = 0.003, Student's t-tests; Supplemen-
tary Fig. 19d).
Discussion
Unraveling the molecular liabilities of T-PLL would be seminal
for therapeutic advancements in this devastating disease. In a
large T-PLL cohort we integrated multi-level genetic alterations
and delineated from mechanistic models that constitutive acti-
vation of TCL1A cooperates with dysfunctional ATM to drive
transformation. This unique lesional partnership is not observed
in other T-cell lymphomas52,53.
Virtually every case (94.6%) fulﬁlling the WHO classiﬁcation
criteria for T-PLL1,52, demonstrated here a genomic rearrange-
ment involving a TCL1 gene and/or its abnormal expression.
TCL1A can enhance signals from the most central growth
receptor of T-cells, the TCR5. As suggested here also from
TCL1A-initiated murine T-PLL, this primary step toward per-
turbation of a protective T-cell homeostasis54 likely entails
additional downregulation of negative TCR regulators (e.g.,
CTLA4, SLAMF6), resulting in augmented TCR net activation.
Fittingly, there were no recurrent mutations in TCR pathway
genes, unlike in nodal mature T-cell lymphomas55,56.
As a phenotypic hallmark of T-PLL, we identiﬁed a pro-
nounced genomic instability, demonstrated by complex losses
and gains and novel molecular hybrids. The global signature of
nucleotide exchanges indicated cumulative genotoxic insults in a
repair deﬁcient precursor cell. ATM was the gene most recur-
rently affected (86%, Fig. 6) by allele deletions (37%) and/or
clonally dominant mutations (65%). The previously undisclosed
clustering of the mostly missense mutations in ATM’s FAT and
PI3K-domains ﬁts well with the proﬁle of ATM variants from
>5400 cancer genomes43.
It has been shown that ATM PI3K-domain dead (KD) alleles
are more oncogenic than the ATMnull scenario43,57. Furthermore,
the ATM kinase domain seems dispensable for recruitment to
damage sites43,57. This is in agreement with the residual, albeit
diminished, damage sensing, and platform recruitment, observed
here. It is therefore attractive to speculate that the expressed
mutated ATM in T-PLL is hypomorphic only with respect to
selective ATM functions. In fact, a robust activation of the het-
erochromatin factor KAP1 was frequently seen (Supplementary
Fig. 16a, b) and may represent a GOF branch of altered ATM, in
resemblance of oncogenic empowerments of mutated p5358. In
indirect support of this theory is the assumption that an ATMnull
constellation is likely disadvantageous given the reported absence
of ATM promoter silencing in T-PLL59 and a complete lack of
cases with biallelic ATM losses here (Fig. 5b).
Obviously, major ATM/p53-mediated branches of the DDR to
restore genome integrity or to execute safeguarding responses,
e.g., to oncogenic stressors or therapy, are insufﬁcient in T-PLL.
This might also be due to incomplete compensation by stand-in’s
(i.e., ATR) or supplementing defects of other DNA repair genes,
as we detected this in the few cases with unaffected ATM.
Importantly, we provide ﬁrst hints that consequences of func-
tional ATM deﬁciencies (e.g., in regulated redox homeostasis or
maintenance of telomere length18,32) are aggravated by the pro-
survival or other speciﬁc effects of TCL1 (Figs. 7, 8). In support,
we previously showed TCL1A to augment mitochondrial ROS
biogenesis60. As full ATM incompetence per se is pro-apoptotic,
the coinciding impact of TCL1 likely perturbs such protective
programs making this a potent leukemogenic liaison. In fact,
TCL1A can rescue the apoptotic phenotype of A-T cells while
potentiating their chromosome fragility15,61.
Among the cataloged aberrations, the most recurrently affected
functional branch was the DDR. However, at the regulatory level
the category of epigenetics, predominantly deﬁned by histone
modifying molecules (EZH2, KMTs, and HDACs) was most fre-
quently involved (Fig. 6). Intriguingly, chromatin modulation is
an increasingly recognized determinant of proper DSB processing
and dictates treatment resistance46,47,49.
The spectrum of other pivotal alterations included ampliﬁed
programs of MYC or miR-based dysregulations (e.g., AGO genes,
MIR34 cluster). Subclonal mutations in JAK/STAT genes were
detected in 61.6%, a frequency that is in agreement with recent
reports21–24,42,62. Nevertheless, their differential GOF effects need
more thorough alignments with inhibitor sensitivities62.
A central mechanistic ﬁnding was the inability of T-PLL cells
to mount a DSB-induced activation of p53. This can explain the
clinical chemo-refractory behavior of T-PLL. In contrast to many
cancers63, the incidence of p53 disrupting genomic lesions in T-
PLL is surprisingly low. Our data implicate that in T-PLL mainly
dysfunctional proximal ATM renders p53 inactive. Since ATM
kinase activity and p53 de-repression stand in a synthetic lethal
relationship64 and in light of the need for non-conventional
therapies in T-PLL, we devised here a promising interventional
strategy. P53 reactivation by MDM2-interference was highly
synergistic with DAC inhibition of histones and central relay
proteins, including ATM and p53.
Fig. 7 T-PLL cells show an aberrant DDR linked to hypofunctional ATM. a Reduced telomere lengths (ﬂow-FISH, age-correlated) in T-PLL (1 telomere
ﬂuorescence unit (TFU) corresponds to 1 kb pairs; p< 0.0001, Student’s paired t-test); see also Supplementary Fig. 14a–c for WGS-based analyses and
associations with ATM lesions. b Immunoﬂuorescence (IF) microscopy. Impaired nuclear translocalization of ATM in T-PLL upon DSB induction at 1 h
exposure to 50 µM Etoposide (independent of genomic ATM status). Left: ImageJ-quantiﬁed mean ﬂuorescence intensities (MFIs) for nuclear signals
(dashed medians). Healthy-donor PBMCs 78.6% vs. T-PLL 42.5% (p< 0.0001, Student’s t-test). Right: representative samples (scale bar= 5 µm; entire set
in Supplementary Fig. 14d). c Aberrant kinetics of DSB-induced foci in T-PLL cells. Left: experimental outline and exemplary IF microscopy (scale bar= 5
µm). Right: summary of quantiﬁcations of yH2AX foci (30 nuclei/case; mean with SEM) in 6 samples of healthy-donor T-cells vs. 23 T-PLL with examples
represented by individual focus counts over time and immunoblots (mean with SEM; Student's t-test, ***p< 0.0001). Abnormal (not resembling the
pattern of normal T cells) formation and kinetics of yH2AX foci in 19/23 T-PLL: hardly any or delayed induction (5/19), as well as inefﬁcient/protracted
removal (14/19). In 4 cases the pattern resembled the one of normal T cells (‘regular’). The entire set of yH2AX IF and a summary of densitometries from
all immunoblots are provided in Supplementary Fig. 15
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Overall, the presented molecular proﬁles and novel functional
insights allowed the formulation of a ﬁrst integrative model of T-
PLL leukemogenesis (Fig. 10). However, this has to be expanded
on at various levels. Also, the T-cell permissive cooperation
between TCL1 and ATM needs to be further interrogated for the
concise pathway overlaps and the exact modes of checkpoint
abrogations through TCL1. This also has to consider the sig-
niﬁcance of a protein–protein interaction of TCL1 with ATM65.
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Methods
Patient samples. Primary T-PLL cells were isolated from peripheral blood (PB) of
111 T-PLL patients diagnosed according to WHO criteria1,52. Differential diagnosis
was based on clinical features, immunophenotyping (ﬂow-cytometry and his-
tochemistry; including TCL1A/MTCP1 expression), FISH/karyotypes, and mole-
cular studies (e.g., TCR-monoclonality). Human tumor samples were obtained
from patients under IRB-approved protocols following written informed consent
according to the Declaration of Helsinki. Collection and use have been approved
for research purposes by the ethics committee of the University Hospital of
Cologne (#11–319). The cohort was selected based on uniform front-line treatment
(87% of cases) with either single-agent alemtuzumab or ﬂudarabine-mitoxantrone-
cyclophosphamide (FMC) plus alemtuzumab chemo-immunotherapy (similar
efﬁcacy, refs. 3,4,66) as part of the TPLL14 (NCT00278213) and TPLL2
(NCT01186640, unpublished) prospective clinical trials or as included in the
nation-wide T-PLL registry (IRB# 12-146) of the German CLL Study Group
(GCLLSG; Supplementary Data 1).
Patients had a median age of 66 years at diagnosis and included 1.5-times more
men than women. Overall survival (OS) was measured as the time from diagnosis
to disease-speciﬁc event or censoring. Kaplan–Meier curves were compiled with
PRISM6; with log-rank statistics for 2-group comparisons.
A small number of samples from other entities was included as references: T-
cell large granular lymphocytic leukemia (T-LGL, n = 2) for WES and telomere
length assessments, as well as Sézary syndrome (SS, n = 2) and chronic lymphocytic
leukemia (CLL, n = 4) for telomere length assessments.
Flow cytometry. Flow cytometry was performed on a Gallios (BeckmanCoulter)
cytometer, using antibodies against human CD3 (clone Hit3a), CD4 (clone OKT4),
CD5 (clone UCHT2), CD7 (clone 6B7), CD8 (Hit8a), CD45 (clone 2D1), and
TCL1A (clone 1–2167), all from BioLegend. Intracellular staining was performed
according to the manufacturer’s instructions using the IntraPrep kit (Beck-
manCoulter). We observed CD4 single positivity in 58%, CD8 single positivity in
16%, and CD4/CD8 double positivity in 24% of cases.
Magnetic-bead based cell enrichment. Peripheral blood mononuclear cells
(PBMCs) of T-PLL patients or healthy volunteers were obtained by density gra-
dient centrifugation (Histopaque, Sigma-Aldrich). DNAs of matched tumor/
germline (t/g)-pairs were obtained after magnetic-assisted cell sorting (MACS),
separating CD4+ or CD8+ T-PLL cells from non-tumor hematopoietic cells with a
ﬁnal purity of >98% (Supplementary Fig. 1b). We conceptualized this T-cell
enrichment to involve a sequential 2-step separation process of which each was
carried out according to the manufacturer’s (Miltenyi Biotec) instructions: (1)
positive enrichment of T-PLL tumor cells followed by (2) depletion of residual T-
PLL cells from the ﬂow-through obtained from step 1 to recover a pure non-tumor
cell fraction. According to the predominant immunophenotype, samples were ﬁrst
enriched for CD4+ (#130-045-101, Miltenyi Biotec) or CD8+ (#130-045-201,
Miltenyi Biotec) lymphocytes using microbeads of the MACS system (Miltenyi
Biotec) and LS Columns (#130-042-401, Miltenyi Biotec). (2) For depletion of the
normal control fractions (neutrophils, monocytes, NK-cells, B-cells) by con-
taminating T-PLL cells, LD Depletion Columns (#130-042-901, Miltenyi Biotec)
were used to remove residual CD4+ or CD8+ cells from the ﬂow-through obtained
from step 1. Purity of cell populations was assessed by ﬂow cytometry. PBMCs of
healthy volunteers were enriched for CD3+ pan T-cells (regular CD4+/8+ ratio of
1.5–2.5) or CD45RO+ pan memory T-cells using MACS beads (130-050-101 (CD3
+) and 130-091-893 (CD45RO+), Miltenyi Biotec).
Cell cycle analysis. Flow-cytometry based cell cycle analysis was performed
according to standard protocols. Brieﬂy, cells were collected, vortexed intensely in
Nicoletti buffer (0.1% w/v Sodium citrate, 0.1% v/v Triton X-100, 50 µg/ml pro-
pidium iodide freshly added) and incorporation was measured.
Murine models for T-PLL and in vivo compound efﬁcacy testing. We re-derived
the originally described hemizygous Lckpr-hTCL1A+/- transgenic (tg) mice10 from
frozen sperm straws (JAX mice research, The Jackson Laboratory) by egg fertili-
zation and embryo transfer. They represent an autochthonous model for human T-
PLL68. Following the early (thymic) onset of constitutive expression of human
TCL1A, according to the activity of the proximal Lck promoter, the animals
develop a CD8+ disease that resembles human T-PLL68.
To test drug efﬁcacies (e.g., Idasanutlin) in vivo, transplantable leukemias/
lymphomas derived from CD2-MTCP1p13 tg mice11 (predominantly blood, spleen,
bone marrow) were i.p. injected into background-matched recipients to facilitate
the generation of uniform cohorts, which is not possible in the original systems due
to long latencies and their wider ranges (despite 100% penetrance) of clinical
disease onset. The CD2-MTCP1p13 tg system is a T-PLL model analogous to
TCL1A-tg, but transplantable lines with slow and fast (latter chosen here) growth
kinetics were only established for the CD2-MTCP1p13 model at the time of study.
1 × 107 cells were i.p. injected into syngeneic recipients (n = 16). Starting on day 11
post transplantation for 5 consecutive days, mice were treated with vehicle control,
or Fludarabine (35 mg/kg days), or Idasanutlin (35 mg/kg). Animals were
randomly assigned to treatment groups (homogeneous distribution as per
leukocyte counts).
In order to test the in vivo pro-leukemogenic cooperation of ATM loss with
TCL1A overexpression, hematopoietic stem cells (HSCs) from Rosa26-CreERT2;
ATMﬂ/ﬂ mice69 were isolated from bone-marrows and retrovirally transduced
in vitro with an expression vector for human TCL1A or GFP. Transduced HSCs
were re-transplanted into sub-lethally irradiated background-matched 8-week-old
recipients and Tamoxifen at 1 mg/day was i.p. injected for 5 consecutive days
12 weeks after transplantation to generate ATM deﬁciency from the recombined
ATMﬂ/ﬂ alleles.
Murine formalin-ﬁxed and parafﬁn embedded tissue material (FFPE) was
stained with hematoxylin and eosin (H/E).
All experiments involving living animals were conducted according to the
German Animal Welfare Act (approval numbers: 20.12.A166 (Lckpr-hTCL1A mice;
LANUV, NRW, Germany), 2012.A394 (in vivo treatment of CD2-MTCP1p13;
LANUV, NRW, Germany), F21/03_RP_Darmstadt (transplantation of sub-lethally
irradiated mice with genetically modiﬁed HSCs; MUKLV, HE, Germany). The
animal experiments served as proof-of-principle/pilot studies, hence, minimal
sample sizes of n = 5 were considered sufﬁcient.
Gene expression proﬁling (GEP). GEP of human T-PLL cells: For sample pre-
paration, PBMCs were isolated from T-PLL patients (>95% purity of T-cells) and
CD3+ T-cells isolated from PB of healthy donors (see paragraph “Magnetic-bead
based cell enrichment” for detailed descriptions on cell puriﬁcation) were sub-
mitted to RNA isolation using the mirVana kit (Invitrogen). GEP analyses were
conducted using Illumina HumanHT-12 v4 BeadChip arrays according to manu-
facturer’s instructions.
Bioinformatics: We used the Illumina proprietary software GenomeStudio v1 to
background-correct and to initially annotate the probes of the HumanHT-12 v4
Expression BeadChip. We ﬁltered samples and genes by detection p-values and
ﬂuorescence intensities for at least 2/3 hits (p < 0.05) to reduce false calls. Batch-
Fig. 8 TCL1A affects ATM functions and cooperates with ATM deﬁciency. a Protracted TCL1A overexpression in HH T-cell leukemia cells mediates
telomere shortening (ﬂow-FISH; Supplementary Fig. 17b–d for controls and qRT-PCR based validations, mean with SEM; Student's t-test). b H2DCFDA-
based measurements of ROS induction upon γ-irradiation (10 Gy) comparing parental Hut78 T-cell leukemia cells to their derivatives of stable TCL1A
transfection. Left: examples of H2DCFDA ﬂuorescence readout 48 h post irradiation, one representative experiment shown. Right: quantiﬁcation of mean
ﬂuorescence intensity (MFI, n= 3 biological replicates, mean with SEM) relative to Hut78 cells without irradiation (p= 0.017, Student's t-test). c Enforced
TCL1A expression in HH cells (doxycycline-inducible iHH) mediates higher peak focus counts of DSB marks (γH2AX, RAD51, and TP53BP1) and their
impaired resolution in time-lines after washout from a preceding 1 h of Etoposide exposure. Left: quantiﬁed focus counts (mean with SEM; Student's t-
test, ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05); right: representative examples (scale bar= 7.5 µm; controls in Supplementary Fig. 17f–h). d Left: setup
of MEFs (Rosa-CreERT2;ATMﬂ/wt and Rosa-CreERT2;ATMﬂ/KD)76 stably transfected to express human (h)TCL1A. ATM loss was induced through Tamoxifen
treatment over 3 passages resulting in ATM−/wt and ATM−/KD cells. Immunoblots in Supplementary Fig. 18a verify reduced ATM protein and
overexpression of TCL1A. The KD-mutations D2880A/N2885K correspond to D2870A/N2875K in human ATM. Right: γ-irradiation reduced cell viability
(proliferation) as per MTT assay (48 h) with TCL1A mediating a protective effect in scenarios of genetic ATM disruption (mean with SEM; Student's
t-tests). e In vivo model of overexpression of hTCL1A and inducible ATM-abrogation. Left: hematopoetic stem cells (HSCs) of Rosa-CreERT2;ATMﬂ/ﬂ mice
were retrovirally transduced with hTCL1A or a GFP control vector and transplanted into irradiated syngeneic hosts. Recombination of the ATM locus (ﬂ/ﬂ)
was induced by Tamoxifen (TM) injections starting 12 weeks after transplantation (1 mg/day i.p. for 5 consecutive days; further details in Supplementary
Fig. 18c, d and Methods section). Middle: Kaplan–Meier curve showing accelerated T-cell lymphoma/leukemia onset and shorter animal survival of the
ATMﬂ/ﬂ/hTCL1Atg genotype (log-rank tests, time from transplantation to event). Right: evidence of hTCL1A-protein positive T-cells (ﬂow cytometry) in
blood and thymus involved by a CD4+/8+ T-cell tumor (ATMﬂ/ﬂ/hTCL1Atg). H/E stains (scale bar left= 100 µm; right= 400 µm) of one exemplary thymic
T-cell lymphoma (ATMﬂ/ﬂ/hTCL1Atg)
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effects were corrected by the ComBat method which uses an empiric Bayesian
model framework. For literature references to bioinformatics methods and
algorithms see Supplementary Table 2. Since the ofﬁcial Illumina HumanHT-12 v4
Expression BeadChip annotation is outdated, we used the data mining tool
biomaRt, version 75 of the Ensembl data base with R, version 3.1.0, and
Bioconductor, version 2.10.
T-PLLs (n = 70) and normal controls (CD3+ T-cells from 10 healthy donors)
were grouped and tested separately for differential expression using the Student’s t-
test on log-transformed ﬂuorescence values (normally distributed). Fold-changes
(fc) were calculated on the ﬂuorescence values without logarithmic transformation.
False discovery rates (FDRs) were calculated using the R package “q-value”.
Hierarchical clustering was carried out using the R package gplots, version 2.15.0
(distance function: euclidean; clustering: complete linkage). In Fig. 1a, the
dendrogram was manually cut to obtain clusters with unique expression patterns.
Gene expression overlaps between human and mouse were evaluated using Venny.
Functional analyses of (differentially expressed) genes was carried out by Ingenuity
Pathway Analysis (IPA, http://www.ingenuity.com/products/ipa),
ConsensusPathDB (GSOA), Broad GSEA 2–2.2.1, and KEGG/GO enrichment
from the R package STRINGdb, version 9_05.
For identiﬁcation of prognostic GEP signatures, GEPs of T-PLL cases with
longest (>800 days, 5 cases) overall survival (OS; time from diagnosis to death of
disease; no other events included) were compared with GEPs of cases with shortest
OS (<300 days, n = 5) using “Signiﬁcance analysis of microarrays” (SAM) analysis
in survival mode70 (ﬁrst training set of 10 cases). We only considered cases in
which the sampling date was no longer than 6 months from diagnosis and with
similar lymphocyte doubling times (LDTs) at presentation. From an initial most
informative index-set of 5 differentially expressed probes (RAB25, KIAA1211L-
probe1, KIAA1211L-probe2, GIMAP6, FXYD2; FDR< 0.1), linear regression (and
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Fig. 9 Pharmacologic exploitation of the defective ATM/p53 axis. a Summary of genomic lesions (sCNAs, mutations) and gene expression changes
affecting TP53 and its direct regulatory network detected in this series of T-PLL. b ATMSer1981, KAP1Ser824, and p53Ser15 phosphorylation upon 10 Gy
ionizing irradiation in 9 T-PLL; controls: ATM/P53-competent HEK293 cells. Robust pKAP1 induction (e.g., TP052; ATM-wt/CN= 2), as well as reduced
activation is observed (e.g., TP007; ATM-mut/CN= 1.5). Despite at least weak pATM/pKAP induction for most cases, none showed a pP53 response
(irrespective of genomic ATM status). All cases lacked 17p sCNAs and TP53 mutations. Median purity: 97.5% T cells; lanes separated for genotype-based
arrangement (* denotes nonsense mutation). For results on CHEK2 phosphorylation in a subset of cases see Supplementary Fig. 19a. c Idasanutlin (0.3 µM)
reinstated phospho- and acetyl-marks of p53 activity in T-PLL cells. Co-treatment with Bendamustine (1 µM) or Panobinostat (0.01 µM) further enhanced
this, including the apoptotic response (cleaved PARP). Immunoblot of case TP104 (representative of 3) at 24 h. There was no p53 phospho-activation by
Prima-1met, a selective reactivator of mutated p53 (Supplementary Fig. 19b). d In vitro screen for interactions of Idasanutlin (I), Panobinostat (P),
Bendamustine (B), and Olaparib (O) across 13 T-PLL. Each of the 6 combinations was plated in a matrix of 7 concentrations covering a 1000-fold range.
Incubation of samples in duplicates for 72 h and cell viability as per luminescent CellTiter-Glo assay; positive control: 100 μM Benzethonium-chloride;
negative control: DMSO. A delta score reﬂects positive (synergistic) and negative (antagonistic) drug interactions. It is calculated based on a zero-
interaction potency (ZIP) reference model and is computed using the synergyﬁnder R-package (details in Online Supplements). Waterfall plot: ranking of
each combination based on the delta scores of the low dose ranges (1–300 nM) across all samples. Rank-sums over 13 cases signiﬁcantly differed among
combinations (I + P:63, I + B:60, I + O:56, P + B:51, O + B:24, O + P:19; p< 0.0001, one-way Friedman Anova, highest ranks for highest score values).
Combinations of I + P (p= 0.015) and I + B (p= 0.04) were superior to P + B (Wilcoxon rank-sum test). O + B or O + P showed antagonistic relationships in
most T-PLL. Four selected 2D plots illustrate the distribution of synergistic (red) or antagonistic (green) interactions over the entire dose range of all 13
cases (positive controls in red in upper right corners)
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one outlier removal by setting OS< 200 days, second training set of 9 cases),
followed again by SAM analysis (survival mode), resulted in a 2-gene/3-probe set
(ILMN_1791826 mapping to 4 transcripts including RAB25-001/ENST00000361084
responsible for standard protein ENSP00000354376; ILMN_1776121 and
ILMN_3243366 both mapping to KIAA1211L-001/ENST00000397899 responsible
for standard protein ENSP00000380996; no other probes mapping to both genes) as
the most robust predictors (only when combined). Their probe sets were used to
calculate an expression index (via additive model ﬁt using Tukey’s median polish
procedure) on the test set of uniformly treated 40 cases of the GEP-analyzed T-PLL
cohort (9 cases of training set (above) excluded) fulﬁlling the respective criteria
(available GEP and OS data). Kaplan–Meier curves (log-rank tests for differences)
were created based on stratiﬁed values per patient of this “2-gene/3-probe
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Fig. 10 Proposed model of T-PLL development. Top: Projections from an ‘unaffected’ thymic emigrant (left) compared to the scenario of a post-thymic T-
PLL precursor (right box) with inappropriate expression of TCL1 and deﬁcient ATM. Effects of this postulated initiating core lesion of TCL1up/ATMdef on the
key signaling branches and functions of ATM are highlighted by differential arrows. It includes perturbation of some of ATM’s safeguarding tasks by TCL1
resulting in cell-death evasion. The ‘TCL1’-lesion refers to the deregulation of any TCL1 family member. TCL1up/ATMdef jointly confer a functional signature
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prognostic expression index”. Ranking the cases solely based on these expression
indices, the 5 T-PLL with the lowest values indeed showed signiﬁcantly superior OS
(only 2 of these 5 cases received an allogenic stem cell transplantation) over those
with higher expression index values (index fc = −1.62; Supplementary Fig. 2e).
GEP in murine T-cell leukemia: For sample preparation, murine spleens
removed post-mortem were mashed through a 100 μm cell strainer (BD
Biosciences) and lymphoid cells were isolated using density gradient centrifugation.
Cells were subsequently enriched for CD8+ lymphocytes using MACS beads (130-
049-401,Miltenyi Biotec). RNA was isolated from murine tissues using the
mirVana kit (Invitrogen). We hybridized 3 control RNA samples (pooled from
CD3+ T-cells enriched from 9 spleens of age- and background-matched wt
animals), as well as RNA isolated from CD8+-enriched splenic T-cells of 3 “chronic
phase” and of 5 “exponential phase” Lckpr-hTCL1A+/− mouse lymphoma samples
on Affymetrix Mouse Gene 1.0 ST Arrays. Deﬁnition of stages: “chronic”—30–70%
tumor cells in PB and spleen, average age 12 months; “exponential”—mean PB
lymphocyte doubling time (LDT) 12 days (SEM 0.8), >80% tumor cells in PB,
>90% in spleen, average animal age 15 months.
Bioinformatics Arrays were pre-processed, background-corrected (RMA),
quantile-normalized, and separately analyzed (chronic phase vs. ctrl., exponential
phase vs. ctrl.) with the “affy” R-package. Annotation of mouse probe sets and
human orthologues was carried out with biomaRt. We did not only overlap
Ensembl IDs, but converted MGI gene names and overlapped them with ofﬁcial
gene symbols as well.
Somatic copy-number alterations (sCNAs). Human T-PLL cells: For sample
preparation, DNAs were isolated from PBMCs of T-PLL patients (n = 83, >95%
purity of T-cells) that included 13 CD4/CD8-enriched/depleted tumor/germline (t/
g) pairs (see chapter “Magnetic-bead based cell enrichment” for details on cell
puriﬁcation) using the QIAamp DNA Kit (Qiagen). SNP-array analyses were
conducted using Affymetrix SNP 6.0 chips according to manufacturer’s
instructions.
Bioinformatics: To globally infer on sCNAs across the T-PLL genome, the T-
PLL data sets were compared to the pooled controls (non-tumor hematopoietic cell
DNA as ‘germline’ from T-PLL patients, n = 13) obtained by the Affymetrix Power
Tools, version 1.14.2 with duplicate SNP/CN markers (by identical position)
removed. We segmented the called SNP/copy number (CN) markers by the
Circular binary segmentation (CBS) algorithm (default options, p< 0.01) within
the DNAcopy R-package and converted the output ﬁles to .seg ﬁles to view them in
the “Integrative Genome Viewer”. Since the CBS algorithm only reports
signiﬁcantly altered segments/regions and therefore disregards gene structure
(perhaps splits them in two or more segments), we mapped regions on gene CDS
(based on version 75 of the Ensembl annotation) within the GenomicRanges R
package, version 1.16.4, and clustered CNs by gene names and 100 kb regions with
the gplots R package. We calculated the frequency by which samples surpassed CN
thresholds (CN< 1.5 for losses, CN > 2.5 for gains) enabling the identiﬁcation of
the minimal (common) deleted or ampliﬁed regions (MDRs/MARs) and their
prevalence across the T-PLL cohort. Hot spots of sCNAs were identiﬁed by visual
inspection, by genes (CDS ranges) assigned to segments called by the CBS
algorithm as well as by conﬁrmatory GISTIC2.0 analyses (with removal of
centromeric and telomeric regions with options: —smallmem 1 —broad 1 —brlen
0.9 8—conf 0.99 —armpeel 1 —qvt 0.05).
Loss-of-heterozygosity (LOH): To evaluate CNNLOH (copy-number neutral
LOH)/UPD (uniparental disomy), we focused on those genes that show LOH and
are in a biallelic state (CN between 1.9 and 2.1). We obtained genotypes from the
SNP array data using Affymetrix Power Tools, version 1.14.2, and the Birdseed
algorithm, and mapped speciﬁc SNPs to the genes by version 75 of the Ensembl
annotation.
Meta-analysis A meta-comparison of published data on neoplasms hybridized
to Affymetrix GenomeWide SNP 6.0 arrays available at GEO was performed to
compare the spectrum of sCNAs with the one of our T-PLL data set (references in
Supplementary Table 2). The HapMap data set “GenomeWideSNP_6.hapmap270.
na32.r1.a5.ref” obtained from the Affymetrix support site served as a reference.
Each sample was analyzed via CBS and those with signiﬁcant gains or losses (CN >
2.5 or CN < 1.5) were selected. We grouped these segments into region size bins for
each sample, i.e., one for segments of size from 1 to 1000 bp, one for 1001 to
10,000 bp, and so on. This enabled comparisons between the CN spectra across
experiments and entities.
Murine T-cell leukemia: We hybridized DNA samples (QIAamp DNA Kit,
Qiagen) onto the Affymetrix MOUSEDIVm520650 chip. We compared 4 controls
(DNA isolated from normal liver tissues of age- and background-matched wild-
type mice) to 3 ‘chronic phase’ and 5 ‘exponential phase’ (deﬁning features in "GEP
in murine T-cell leukemia") splenic isolates from T-cell leukemia / lymphoma
bearing Lckpr-hTCL1A+/- mice.
Bioinformatics Arrays were pre-processed and separately analyzed (‘chronic
phase’ vs. ctrl., ‘exponential phase’ vs. ctrl.) with the ‘mouseDivGeno’ R-package.
Whole-exome sequencing (WES). Sample preparation: DNAs were isolated from
CD4 or CD8 enriched tumor/germline (t/g)-pairs (n = 13) and from CD45RO+
enriched memory T-cells from healthy donors (see “Magnetic-bead based cell
enrichment” for details on cell puriﬁcation) using the QIAamp DNA Kit (Qiagen).
Exomes were prepared by fragmenting 1 μg of DNA using sonication technology
(Bioruptor, Diagenode, Liège, Belgium) followed by end repair and adapter ligation
including incorporation of Illumina TruSeq index barcodes. After size selection and
quantiﬁcation, pools of 5 libraries were each subjected to enrichment using the
SeqCap EZ v2 Library kit from NimbleGen and following the NimbleGen SeqCap
EZ Library SR User’s Guide version 3.0 protocol71.
Bioinformatics: We sequenced 17 T-PLL (t/g)-pairs and 37 T-PLL tumor-single
samples (with F/U samples on 5 of them). To establish the ‘T-cell-aging’
-associated mutational signatures, we analyzed memory T-cells isolated from 3 age-
matched healthy donors (ages 61, 63, and 65 years; median for the T-PLL cases was
66 years) as well as memory T-cells from 3 young healthy donors (ages 22, 28, and
31 years). To exclude most inter-individual variations, WES proﬁles of each “old”
memory T-cell samples were compared to each “young” memory T-cell sample
separately and only recurring SNVs (3/3) that passed the ‘pseudosomatic’ ﬁlters
(see above) were kept. Median numbers of G> T mutations in affected patients (n
= 15/17) and median numbers of C>A mutations in affected patients (n = 12/17)
were compared to all remaining substitutions and those numbers found in memory
T-cell comparisons (Fig. 4c) with Odds ratios and Fisher’s count test.
We used the Illumina HiSeq2000 at the Cologne Center for Genomics (CCG),
except for 8 t/g-pairs and 8-tumor singles that were analyzed at another facility
(University of Michigan, collaborator/co-author K.E.-J.) for evaluations of data
robustness. The cumulative exonic region (based on Ensembl 71 annotation) with
at least 30× average depth coverages (calculated with GATK DepthOfCoverage)
were: 38,120,877 and 38,599,542 bp (~38.4 Mbp) for the CCG facility and
27,182,553 bp (~27.2 Mbp) for the outside facility21; average depth: 43× and 45×
for the CCG facility and 23× for the outside facility; median insert-sizes: 167 and
200 bp for the CCG facility and 263 bp for the outside facility (calculated with
Picard 1.88). Assembly was performed with BWA 0.6.2 on the UCSC hg19
reference genome. After sorting and indexing of the resulting BAM ﬁles with
SAMtools, version 0.1.19, PCR duplicates were removed with Picard 1.88. Exonic
regions were re-aligned and the base quality scores were re-calibrated according to
the Genome Analysis Toolkit Best Practices recommendations. For ‘somatic’
comparisons we used the same-patient pair-matched germline if available,
otherwise a representative germline sample obtained from the same batch
(‘pseudosomatic’) was used.
For somatic single-nucleotide variants (sSNVs) MuTect 1.1.4 and MuTect v2
were employed with default parameters, while for somatic indels (insertions and
deletions) VarScan 2.3.6 was used. We also used Genome Analysis Toolkit
UniﬁedGenotyper 2.7–4 for germline SNVs and indels. Mutations were annotated
using ANNOVAR with the associated packages NCBI dbSNP 138, COSMIC 70
WGS, ESP6500-SI (W. NHLBI GO Exome Sequencing Project Seattle), 1000G
April 2012, ExAc0.3 (Exome Aggregation Consortium, Cambridge, MA (http://
exac.broadinstitute.org [06/08/2015 accessed via ANNOVAR])), NCI60, and
clinVar release 20150330.
Pseudosomatic SNVs and small indels were ﬁltered (i) by exclusion of potential
SNPs by eliminating mutations with a 1000G and/or ESP6500-SI frequency and/or
ExAc0.3 minor allele fraction (MAF) ≥0.01 (PopFreq <0.01 considered as SNV or
indels), (ii) by determination of genes that are enriched for likely damaging
mutations using PROVEAN (for indels), PolyPhen2 (score ≥0.957) and SIFT (score
≤0.05) algorithms, (iii) by controlling the false-discovery rate (FDR) by a statistical
comparison of observed and expected mutation rates (WUSTL MuSiC), and (iv) by
inclusion of mutations that are annotated within the COSMIC data base v70. For
our paired WES cases, we applied more lenient ﬁlters (standard MuTect) and
skipped (ii). Since we observed a high portion of C:G>A:T transversions indicative
for oxidative DNA damage (8-oxoguanine (8-oxoG) lesions), we applied additional
ﬁlters similar to the ones used in Costello et al. and Chen et al.37,38. First, we ran
MuTect v2 to obtain FoxoG ratios (fraction of alternate allele supporting reads with
e.g., G> T on read 1 and C>A on read 2 or vice versa; not to be confused with
“strand bias”) and tumor loads (estimated log odds that the observed number of
alternate allele reads from the tumor sample could have arisen from a reference
allele) for each mutation we previously screened with the less stringent MuTect
v1.1.4.
We discarded all mutations with tumor fractions below 0.5 that were not found
by MuTect v2 (and therefore no FoxoG ratios and tumor loads available). We
further discarded all mutations not surpassing the empirical ﬁlter of Costello
et al.38 and thereby having a potential allelic imbalance: tumor loads ≥10 + (100/
3) × FoxoG. A Lego plot of SNV frequencies with trinucleotide contexts was
prepared using a modiﬁed source code by developer C. Wardell (https://github.
com/cpwardell/ 3dbarplot).
We calculated the mutational frequency without background-correction, by
dividing the average number of somatic mutations per sample per target Mb
(NimbleGen SeqCap EZ Exome v3: 64,000,000 bp). Since we also ran samples on
the lower targeting SeqCap2 and Agilent SureSelect Human All Exon V6, the
mutational frequency is actually underestimated (conservative estimate). Mutation
frequencies of other neoplasms were obtained with the same caller (‘Published
validation rates of calls made by previous versions of MuTect in coding region’).
We inferred structural variations by mapping distance and order of paired-end
reads using DELLY (version 0.7.2) and ﬁltered for a minimum genotype quality of
200, for no LowQual entries, minimum depth of 5 reads, and for split-read support
(more precise breakpoint localization). For structural variations affecting TCL1
oncogenes, we applied more lenient ﬁlters (genotype likely somatic). CN neutral
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entries in the database of genomic variants (GRCh37_hg19_variants_2013-07-23)
were further used to ﬁlter within a 1 kb breakpoint window. The resulting list was
then annotated with the COSMIC SV data sheet (02/04/2014 last modiﬁed; liftOver
from hg38 to hg19 with UCSC Utilities web-GUI) and visualized with circos 0.64.
Chromotripsis patterns were evaluated as previously described35,36.
For the detection of sCNAs in WES data, we used “EXCAVATOR2“ at default
settings, which evaluates signiﬁcant drops of coverage. As the reference set, we
pooled all germline samples obtained from the same batch of the respective tumor
sample. Potential microsatellite-instability (MSI) was assessed using MSIsensor
with default settings.
Sequential samples were compared in a pair-wise fashion: sample at F/U vs.
sample at diagnosis. Estimations of cellular prevalences and clustering of mutated
populations were obtained by the Bayesian framework PyClone using its own
Binomial density model with 10,000 MCMC iterations and default priors (shape =
1.0; rate = 0.001; initial concentration = 1.0; alpha = 1; beta = 1). As input, we only
considered mutated genes that were among those TOP 50 that increased the most
in VAF between ﬁrst and second time point or those that were only mutated at
second time point, and were simultaneously members of enriched pathways (p<
0.01; see also Supplementary Data 19): e.g., “TP53 Regulates Transcription of DNA
Repair Genes” (Wikipathways), “Notch Signaling Pathway” (Wikipathways), “TP53
Regulates Transcription of DNA Repair Genes” (Reactome), “TCR” (NetPath),
“Interleukin-4 and −13 signaling” (Reactome), and “JAK STAT MolecularVariation
2” (INOH).
Whole-genome sequencing (WGS). Sample preparation: DNA extraction was
performed as described under "Whole-exome sequencing (WES)". Sample pro-
cessing for WGS was performed according to standard techniques.
Bioinformatics: We sequenced 3 T-PLL t/g-pairs and one T-PLL tumor single
on an Illumina HiSeq2000 using the same settings as for WES analysis, except for
different target regions for alignment and mutation calling, including non-coding
(nc) regions. The Broad Institute hg19 Catalog of long-intergenic non-coding
RNAs, Gencode lncRNAsv7 summary table (05/02/2012 accessed), mirBase Release
20 (around 2000 validated and over 4000 predicted miRNAs), FANTOM5 hg19
enhancer sites (accession 29/11/2012), and promoter regions derived from version
71 of the Ensembl annotation (−2000 to +200 bp of TSS) were used. Telomere
lengths were analyzed using ‘telseq’.
Whole-transcriptome sequencing (WTS). Sample preparation: PBMCs of T-PLL
patients (>95% purity of T-cells) and CD3+ T-cells isolated from PB of healthy
donors (see “Magnetic-bead based cell enrichment“ for details on cell puriﬁcations)
were subjected to RNA isolation using the mirVana kit (Invitrogen). WTS analyses
were conducted using the Illumina HiSeq2000 platform according to standard
techniques.
Bioinformatics: Reads were mapped to the human reference genome, build
GRCh37, using Tophat v2.0.10 and the genome annotation based on the Ensembl
data base, version 75. After duplicate removal, the read counts were further
processed using DESeq v1.14.0 and DEXSeq v1.16.0 to analyze differentially
expressed and differentially spliced genes between all 15 T-PLL samples and 4
healthy-donor derived control T-cell samples. Fusion events were analyzed using
Tophat-Fusion and the associated downstream ﬁltering pipeline (Tophat-Fusion
Post). Alternatively with less stringent quality ﬁlters, but with calculation of
oncogenic potential, we used oncofuse with two complementary ﬁlters: passenger
probability <0.001, driver probability >0.999 and minimum support reads >10, as
well as passenger probability <0.01, driver probability >0.99, and minimum
support reads >100. In a validation approach we aligned reads with STAR_2.5.2a
in 2-pass mode to the GRCh37/hg19 reference genome. Sub-routine STAR-Fusion
was used to evaluate fusion transcripts. General overlap to results obtained by
TopHat-Fusion was quite low (sample-wise: 21/96; global by gene partners: 30/96);
however, all prominent hits were conﬁrmed: TCL1A-TRAJ49 as well as PLEC with
other genes on chr.8 (i.e., ZC3H3 or SHARPIN). WTS samples were screened for
SNVs (as anchor points for allele-speciﬁc expression) with GATK
UniﬁedGenotyper 2.7–4 and very low quality thresholds
(–ﬁlter_mismatching_base_and_quals–ﬁlter_reads_with_N_cigar-
stand_call_conf5-stand_emit_conf2). Cuffdiff (cufﬂinks-2.2.1.Linux_x86_64) was
used to generate FPKM values (fragments per kilobase of exon per million reads
mapped).
VirusFinder2.0, did not identify any viral transcripts except for J02482/
Coliphage phi-X174, a control in the sequencing run. The integration-site ﬁle was
empty and whole-genome screens did not reveal viral sequences.
Differential exon usage was analyzed using the DEXSeq package, version 1.16.0.
Exons were selected using 5 as a cutoff for linear fold enrichment and 0.01 for the
adjusted p-value, ending up with a list of 1927 alternatively used exon segments in
1091 genes. Among these alternative splicing events, 140 exons in 85 genes
overlapped with events reported for acute myeloid leukemia (AML) and 105 exons
in 67 genes overlapped with events reported for diffuse large B-cell lymphoma
(DLBCL) according to the TCGA SpliceSeq data base. Alternative splicing events in
56 genes are overlapping between all 3 hematologic malignancies (T-PLL, AML,
and DLBCL).
Targeted amplicon sequencing (TAS) and Sanger sequencing. T-PLL tumor
singles of 18 cases were analyzed by a customized targeted-amplicon sequencing
(TAS) panel that we designed. It covered ATM (ex.1–63), JAK1 (ex.9–15), JAK3
(ex.10–17) using the Illumina MiSeq platform, and STAT5B (ex.16) using Sanger
sequencing (see Supplementary Data 22 for oligonucleotides).
Sample preparation: Amplicons were generated using standard PCRs. Products
were puriﬁed using the ZR-96 DNA Clean-up Kit (Zymo Research), and an
equimolar amplicon-pool was prepared for each patient. Library preparation was
conducted using the TruSeq DNA LT Sample Prep Kit (Illumina) with 1 µg
amplicon DNA. Ampliﬁcation was carried out using 8 cycles. The MiSeq Reagent
Kit v3 (Illumina) was used for sequencing and the samples were analyzed on the
MiSeq NGS platform. Library preparation and sequencing was performed
according to the manufacturer's instruction at the Cologne Center for Genomics
(CCG).
Bioinformatics: For read alignment and further read processing, we followed the
same strategy as for WES (above). The Genome Analysis Toolkit Uniﬁed
Genotyper 2.7–4 was used without down-sampling (dCov = 10,000) to call
mutations (SNVs and indels). We calculated the VAF with “bam-readcount”
(https://github.com/ sjackman/bam-readcount, accessed 19/12/2014) with minimal
mapping and a base quality of 20. A Phred-scaled quality of at least 100 and a
depth of coverage of at least 10 was presumed to restrict false positives. We further
used the same ﬁlters as for pseudosomatic mutations in WES.
Sanger sequencing: Primer spanning all regions of interest were designed and
used for PCRs according to standard protocols. PCR products were sequenced
using the Big Dye Terminator Sequencing v3.1 kit and ABI PRISM 3730XL DNA
Analyzer (Applied Biosystems). Capillary electrophoresis was carried out at the
CCG. For electropherogram analysis SnapGene (v2.8.2, SnapGene) and 4Peaks
(v1.8, nucleobytes) were used.
Integrative approaches of bioinformatic analyses. Major analysis steps were
executed through our own ‘Cancer Pipeline’72 within the QuickNGS framework
and downstream Semantic Web applications. Thus, mutation analysis results are
written in the RDF/N3 (resource description framework) format, and stored in a
jetty-6.1.26 servlet engine running an OpenRDF Workbench Version 2.6.10
Sesame server. Combinatorial (with patient data) and multiple data set analyses
(Figs. 4f, 5b, 6a, and Supplementary Figs. 6,7, as well as sample organization was
done by implementing queries that were further processed with the R-package
“SPARQL 1.16”.
Quantitative real-time PCR. Total RNA was extracted from human CD3+ pan T-
cells and murine CD8+ T-cells following manufacturer’s instructions (mirVana,
Invitrogen and RNeasy Mini Kit, Qiagen). Total sample RNA was reverse-
transcribed into polydT cDNAs using SuperScript II reverse transcriptase (Thermo
Fisher Scientiﬁc). Real-time quantitative PCR on human and murine mRNA was
carried out using an ABI 7500 Fast System. Primers of the genes encoding human
and murine β-actin were used as standard references for quantiﬁcation using the 2
(-Delta Delta C(T)) method (see Supplementary Data 22 for Oligonucleotides).
Cell cultures and cell lines. RPMI-1640 medium (Sigma-Aldrich) supplemented
with 2 mM L-Glutamine, 10% fetal bovine serum (FBS) and Penicillin/Strepto-
mycin (100 U/1) was used for in vitro experiments on suspension cultures of
primary T-PLL cells, the T-cell lines HH/iHH-TCL1A and HuT78/Hut78-TCL1A,
the A-T derived B-lymphoblastoid cells, and the 32D cells. Suspension cells were
maintained at a density of 1.0–3.0 × 105 cells/ml and of 1.0 × 106 cells/ml (T-PLL
cells). ATMﬂ/wt and ATMﬂ/KD MEFs (mouse embryonic ﬁbroblasts) were cultured
in DMEM supplemented with 2 mM L-Glutamine, 15% FBS, 1% MEM non-
essential amino acid, 1% Sodium Pyruvate, 0.12 mM 2-Mercaptathanol and
Penicillin/Streptomycin 100 U/1 (PAA). Culturing was done in an incubator at 37 °
C and 5% CO2 with 90% humidity. HEK293T cells were propagated in complete
DMEM medium (10% FCS, 2 mM L-Glutamine, 10 U/ml Penicillin/Streptomycin).
The cell lines HH (ATCC; https://www.lgcstandards-atcc.org), Hut78 (ATCC) and
the A-T patient-derived lines (gift of L. Chessa, Rome, Italy) were originally
acquired in 2011 and before. Only original stock propagated immediately upon
arrival for 2–3 passages was picked for studies and cultures terminated after the
10th round of passaging (4–6 weeks). Upon thawing for experimentation in years
2011–2017, all lines were authenticated by characteristic growth behavior and by
ﬂow cytometry conﬁrming their characteristic immunophenotype. Each thawed
passage was tested for Mycoplasma infection by standard PCR protocols. All used
cell lines are not listed in the latest version 8.0 of the register of cell lines that are
known to be misidentiﬁed through cross-contamination or other mechanisms.
HH/iHH-TCL1A and Hut78/Hut78-TCL1A systems from human CD4+
mature (cutaneous) T-cell leukemia lines: iHH-TCL1A cells of inducible TCL1A
expression were created via genetic modiﬁcation of the parental HH line (TCL1A
negative) by transfection with retroviral expression vectors (TRMPVIR system)
encoding for human TCL1A under control of the Doxycycline-inducible tet-on
promotor (Supplementary Fig. 17) and by subsequent Puromycin-based selection.
TCL1A was induced in iHH cells by exposure to 1 µg/ml doxycycline for 24 h or if
longer then indicated. Stable Hut78-TCL1A transfectants were created through
genetic modiﬁcation of the Hut78 (TCL1A negative) line by transfection with
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retroviral expression vectors (MSCV-puro) encoding for human TCL1A and
subsequent Puromycin-based selection.
The A-T patient-derived B-lymphoblastoid cell lines73 ‘AT65RM’ (ATMΔ/Δ:
c.6573-9G->A/ c.8814_8824del11; ATM protein absent) and ‘AT-CT’ (ATMWT
control from an unaffected relative) were used to assess (ATM related) speciﬁcity of
pKAPSer824 induction.
For detection of levels of reactive oxygen species (ROS) 6-well plates were
coated with anti-CD3 (OKT3, 10 µg/mL) and anti-CD28 (15E8, 20 µg/mL) in PBS
for 1 h at 37 °C. The solution was gently aspirated and T-PLL cells (1 × 106/ml)
were added. Flow-cytometry based analysis of intracellular ROS levels was
conducted using the H2DCFDA dye according to manufacturer’s instructions.
Measurement of ROS induction in MEF and Hut78(-TCL1A) cells after irradiation
(5 and 15 Gy) was performed after indicated timescales using the ROS dye
H2DCFDA, which was added in a ﬁnal concentration of 1 µM and incubated for 30
min at 37 °C. Measurement was done in a plate reader or via ﬂow cytometry.
p-STAT5B responses of T-PLL cells and CD3+ pan T-cells from healthy donors
to interleukins was assessed using IL-7 (5 ng/mL), IL-15 (20 ng/mL), and IL-21
(100 ng/mL), all from PreproTech. Cells were treated with interleukins for 30 min.
Plasmid mutagenesis and transfection. STAT5B variants were generated by site-
directed mutagenesis (QuikChange Lightning Site-Directed Mutagenesis Kit, Agi-
lent Technologies) using a sequence veriﬁed FLAG-tagged human STAT5B
pMSCV-IRES-GFP vector. For primers used please refer to Supplementary Data
22. Sequence and mutations were veriﬁed by Sanger sequencing. Plasmid trans-
fection of HEK293 cells was performed using SuperFect reagent (Qiagen). 32D cells
were electroporated using 5 × 106 cells in 800 µl plain RPMI medium containing 20
µg plasmid DNA. Following electroporation, cells were cultured with RPMI
medium containing 20% FCS and 2 ng/ml IL-3 for 2 days. 5 × 103 electroporated
32D cells were seeded with or without 1 ng/ml IL-3 and viability was assessed using
CellTiter-Glo Luminescent Cell Viability Assay (Promega).
ATMﬂ/wt and ATMﬂ/KD mouse embryonic ﬁbroblasts (MEFs)43 were used to
generate their TCL1A-expressing sub-lines. The TCL1A expression construct was
generated by an insertion of the TCL1A-encoding cDNA sequence into a
commercially available PiggyBac expression vector pJ547-17 (DNA2.0, USA).
Following Amaxa-based nucleofection (Lonza, Germany) of the TCL1A expression
construct, TCL1A-expressing MEF sub-lines were established by the selection of
the stable clone with hygromycin. Transfection efﬁcacy was controlled via TCL1-
APC staining using ﬂow cytometry analysis. Cells were passed three times (48 h
interval) in the presence of 4-hydroxytamoxifen (4OHT, 200 nM) to achieve
respective genotypes via the 4OHT-inducible Cre recombinase (performed
separately for each biological replicate). Genotyping was done using a standard
PCR protocol. For viability assays, MEF cells were seeded in 96-well plates (6 ×
103cells/well) and irradiated with 5 or 15 Gy. After 48 h the colorimetric MTT
assay was performed (for details see “in vitro drug treatment and cell viability”).
FISH analysis and karyotyping. FISH analysis was conducted according to
manufacturer’s instructions using probes targeting AGO2 (customized at Empire
Genomics, Custom FISH Probe, Clone Library: RPCI-11 (RP11), Clone Name:
628B24), CEP8 (Metasystems, XCE8, D-0808-050-OR), and TCRα/TCRδ sequences
(LSI TCR alpha/delta dual color Break Apart rearrangement Probe, 05N41-020,
Abbott Molecular). The latter probe set was used to supplement karyotypic data in
order to conﬁrm inv(14) or t(14;14) associated rearrangements of TCR gene ele-
ments as part of the aberrations that activate TCL1A expression. For metaphase
karyotyping, PB samples were cultured for 72 h under PHA-mediated stimulation.
Cells were arrested using colcemid (Biochrom) and then treated with 0.3%
potassium chloride solution followed by ﬁxation in ice-cold Carnoy’s reagent. Cell
suspensions were dropped onto microscopic slides. Dried samples were stained
using GTG-banding. For interphase FISH analysis, unstimulated cells from PB
were used. Slides were prepared as described above. DNA was denatured for 5 min
at 73 °C in denaturing solution (70% formamide (Sigma), 10% 20X SSC, and 20%
water). Slides were washed in 2X SSC and dehydrated in a 70%, 85%, and 100%
ethanol series for 2 min each. Volumes of 10 µL of speciﬁc FISH-probe were
applied to the slides and coverslips sealed with rubber cement. Following overnight
incubation at 37 °C in a wet chamber, slides were washed in 0.4X SSC/ 0.3% NP-40
for 2 min at 73 °C and in 2X SSC/0.1% NP-40 for 1 min at room temperature.
Volumes of 10 µL of DAPI counterstain solution (Metasystems) were applied to
air-dried slides, which were then sealed using a coverslip and nail polish.
Telomere length evaluation. Flow-FISH analyses for telomere length assessment
were conducted as follows74: samples were prepared for cell denaturation and
mixed with a FITC labeled telomere speciﬁc (CCCTAA)3-peptide nucleic acid
FISH probe (Eurogentec) for DNA-hybridization followed by DNA counter-
staining with LDS 751 (Sigma). Bovine thymocytes were used as an internal
control. Data acquisition was done with a FC-500 ﬂow cytometer (Becton Dick-
inson). All measurements were carried out single-blinded in triplicates. Healthy
control lymphocytes (104 volunteers) were used for age-adaptation of telomere
length. Monochrome multiplex quantitative PCR (MM-QPCR) for determination
of telomere length was performed as previously described75 (see Supplementary
Data 22 for oligonucleotides). T/S ratios were calculated by dividing the number of
copies of the telomere template (T) by the beta-globin template (S)75.
In vitro drug treatment and cell viability. The MDM2 inhibitor Idasanutlin
(Hycultec), the mutant p53 reactivator Prima-1met (GENTAUR), the HDAC
inhibitor Panobinostat (Hycultec), the ATM inhibitor KU55933 (Selleckchem), the
alkylating agent Bendamustine (Astellas Pharma), and the PARP inhibitor Ola-
parib (Selleckchem) were solved in dimethyl sulfoxide (DMSO). For key infor-
mation on the small molecule inhibitors used, including primary references, see
Supplementary Table 3. Drug exposures were performed at the indicated con-
centrations and times. Dosing was based on published ranges and own IC50/LD50
titrations. Apoptosis was determined using dual staining for Annexin-V (AnnxV)
and 7AAD via ﬂow cytometry. The colorimetric MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetra-zolium bromide) assay measured using SpectraMax Paradigm
Plate Reader, assessed metabolic activity of cells and by that viability.
Screening for compound interactions was performed on mononuclear cell
samples from 13 T-PLL patients. Substances were dissolved in DMSO and
dispensed on 384-well plates using Echo 550, an acoustic liquid handling device.
Each drug combination was plated in duplicates in a matrix of 7 concentrations
covering a 1000-fold concentration range. The compounds were dissolved in a
shaker with 5 μL of Mononuclear Cell Medium (Promocell) for 10 min. Twenty
microliters of single-cell suspension (equivalent to 10,000 cells) were transferred to
each well using a MultiDrop Combi dispenser. The plates were incubated at 37 °C
and 5% CO2, and after 72 h cell viability was measured using the CellTiter-Glo
luminescent assay and a Pherastar FS plate reader. The 6 drug combinations were
screened in 384 well plates for each sample. The plate layout consists of 6 wells for
positive controls (100 μM Benzethonium Chloride) and 6 wells negative controls
(DMSO), distributed throughout the plate. Relative percent inhibition is calculated
by subtracting each well from negative control, divided by sum of average positive
and average negative control. The delta score of drug combinations, which is based
on newly developed zero-interaction potency (ZIP) reference model, is computed
using synergyﬁnder R-package.
Irradiation response. Cell lines and primary T-PLL cells were cultured in standard
RPMI-1640 medium (see “Cell cultures and cell lines”) and DNA damage was
induced using gamma irradiation at the indicated Gy-dosages by a BIOBEAM GM
instrument (Gamma-Service Medical) equipped with a Cs137 radionuclide source.
After irradiation, cells were incubated for indicated timescales at 37 °C, 5% CO2
and subsequently collected for immunoblotting, ﬂow cytometry, MTT assay, or
ROS staining, and so on.
Immunoblots. Western blots on whole-cell protein lysates were performed
according to standard techniques. The primary antibodies included: ATM (clone
D2E2), phospho-STAT5BTyr694 (clone C11C5), STAT5B (polyclonal; #9363),
phospho-JAK1Tyr1022/1023 (polyclonal; #3331), JAK1 (clone 6G4), phospho-
JAK3Tyr980/981 (clone D44E3), JAK3 (clone D7B12), phospho-p53Ser15 (clone
16G8), p53 (clone 1C12), acetyl-p53Lys382 (polyclonal; #2525), acetyl-Histone
H3Lys18 (clone D8Z5H), PARP (polyclonal¸ #9542), γH2AXSer139 (clone 20E3),
phospho-TIF1betaSer824 (pKAP1; polyclonal; #4127), TIF1beta (KAP1; clone 4E1),
phospho-Chk2Thr68 (clone C13C1), Chk2 (clone 1C12), and GAPDH (clone
14C10), all from Cell Signaling Technology; ATM (clone 2C1), β-actin (clone c-11),
β-tubulin (polyclonal; sc-9104), and HSC70 (clone B-6), all from Santa Cruz
Biotechnology; phospho-ATMSer1981 (clone EP1890Y) from LifeSpan BioSciences,
c-Myc (R951-25) from Dianova, and MDM2 (clone IF2) from Calbiochem.
Development and use of our anti-TCL1A antibody (clone 1–21) in T-PLL has been
described67. Ago2 antibody (clone 11A9; diluted 1:5–10) was a gift from G. Meister
(University of Regensburg, Germany). All primary antibodies were used at 1:1000
dilutions, except for anti-GAPDH (1:3000 dilution), anti-phospho-Chk2 (1:750),
anti-Chk2 (1:500), anti-MDM2 (1:300), anti-β-tubulin (1:5000), and anti-β-actin
(1:5000). As secondary HRP-coupled antibodies we used: anti-goat (sc-2020), anti-
rat (sc-2303), anti-mouse (sc-2314) and anti-rabbit (sc-2313), all from Santa Cruz
Biotechnology, according to the manufacturer’s instructions. Western blots were
developed using Western Bright ECL (Advansta). Chemiluminescence was detected
using Autoradiography Film Blue (Santa Cruz Biotechnology), and the developer
machine CAWOMAT 2000 IR (CAWO Solutions). Signal intensities were recorded
by densitometry (ImageJ software). Supplementary Fig. 20 provides uncropped
images of all immunoblots shown in the main ﬁgures (Figs. 7c, 9b, c).
Immunoﬂuorescence microscopy. Cytospins were prepared using 1 × 105 pri-
mary T-PLL or HH/iHH-TCL1A cells in a Cytospin3 cytocentrifuge (Thermo
Shandon) at 800×g for 5 mins. Cells were ﬁxed for 15 min at 4 °C in 3% PFA with
2% sucrose in PBS. Cell permeabilization (10 mM PIPES, pH 6.8, 100 mM NaCl,
300 mM sucrose, 3 mM MgCl2, 1 mM EDTA, 0.5% Triton X-100), and cytoske-
leton stripping (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2, 2%
Tween20, 0.5% sodium deoxycholate) were performed on ice each for 10 min.
Blocking was carried out using 5% BSA/PBS for 45 mins at room temperature.
Primary antibodies against yH2AX (clone JBW301 Millipore/Merck Chemicals),
RAD51 (polyclonal; #ab63801, Abcam), TP53BP1 (Cell Signaling Technology), 8-
Hydroxyguanosine (clone N45.1, Abcam), and ATM (clone 2C1, Santa Cruz
Biotechnology) were used at 1:200 dilution in 5% BSA/PBS overnight at 4 °C in a
wet chamber. The secondary antibodies donkey anti-mouse (AF488 labeled) and
donkey anti-rabbit (Cy3 labeled) (Jackson Laboratories/Dianova) were diluted at
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1:400 in 5% BSA/PBS. Incubation was carried out for 3 h at room temperature.
Slides were washed three times for 10 min with 5% BSA/PBS and once shortly with
PBS to remove BSA. Slides were coverslipped with Mowiol containing Hoechst
33258 (140 μM). Samples were analyzed using an Axio Scope.A1 ﬂuorescence
microscope (Zeiss). Representative images were captured using AxioVision soft-
ware. Quantiﬁcation of yH2AX, RAD51, and TP53BP1 foci was performed by
manually counting the foci in 30 nuclei per time-point (means with SEM calcu-
lated). Cytosolic or nuclear ATM localization was assessed by measuring ﬂuores-
cence intensity using the ImageJ software. Fluorescence signals derived from the
whole cell and from the nucleus were determined separately in 5 cells per sample
and condition. Whole-cell ﬂuorescence was set to 100% to calculate the percentile
distribution of nuclear ﬂuorescence intensity. 8-Hydroxyguanosine (8-OxoG) levels
were accordingly determined over 30 whole cells.
Data availability. Deep sequencing data supporting the ﬁndings of this study are
subject to controlled access at the European Genome-phenome Archive (EGA)
with accession number EGAS00001002744. SNP-array and microarray-based GEP
data are available at Gene Expression Omnibus (GEO) with accession number
GSE107513. WES data on 8 t/g pairs21 and TAS data for JAK/STAT genes on 4
cases62 had been published previously.
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